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SYNOPSIS 
Several aspects of the cellular immune response in patients 
with tuberculosis were examined. 
xvii 
A subset of patients were noted to have persistent 
spontaneous peripheral blood lymphocyte proliferation as 
assessed by in-vitro 3 [H]thymidine incorporation. Receptor 
studies (i.e. identification of the interleukin-2 receptor 
by immunostaining and dose-dependent blocking with anti-
interleukin-2-receptor antibody) confirmed that the 
proliferation was interleukin-2 dependent. The kinetics of 
the proliferation, the strict requirement for accessory 
cells (as determined in cell separation experiments) and the 
fact that adherent cell supernatants obtained from these 
patients significantly stimulated cells from control PPD 
responders suggested that persisting mycobacterial antigen 
was responsible for the phenomenon. 
Since cytotoxic T cells have been invoked as an important 
protective mechanism against Mycobacteria, evidence for 
their induction was sought in patients with tuberculous 
pleuritis. PPD-specific cytotoxicity in tuberculous pleural 
effusion lymphocytes was found to be augmented and 
accelerated when compared to autologous peripheral blood, 
control peripheral blood or non-tuberculous pleural 
effusions. The cytotoxicity could only be demonstrated in 
15-hour chromium release assays. Cell subset enrichment by 
panning indicated that the cytotoxicity was mediated by CD4+ 
cells. The cytotoxicity was MHC class II restricted. Antigen 
non-specific cytotoxicity was also noted and found to be due 
to NK cells. All attempts to demonstrate PPD-specific 
cytotoxicity in conventional 4-hour chromium release assays 
failed. This included experiments utilizing cytoplasmic 
loading by osmotic lysis of pinosomes in order to introduce 
soluble PPD or BCG into the class I pathway of antigen 
processing. 
The proliferative response of pleural effusion lymphocytes 
to PPD was also found to be accelerated. The diagnostic 
value of this finding was evaluated. 65% of 31 patients with 
tuberculous pleuritis had an accelerated proliferative 
response. The phenomenon was not seen in non-tuberculous 
effusions. 
Proliferative and cytotoxic responses of pleural effusion 
lymphocytes to the recombinant 65 kDa heat shock protein of 
Mycobacterium Bovis BCG were determined. A marked 
compartmentalization of the proliferative response was 
observed with a much higher response by pleural effusion 
lymphocytes as compared to autologous peripheral blood. Non-
tuberculous effusions were not reactive. Pleural effusion 
lymphocytes stimulated with the 65 kDa antigen also showed 
antigen-specific lysis of autologous adherent target cells 





Tuberculosis is probably the oldest infection known to man 
(1). Reports of its existence date back to antiquity (1,2). 
Although much progress has been made, the disease continues 
to be a major problem worldwide (2,3). Developing countries 
carry the brunt of the burden, with Africa having the 
highest incidence (4). Approximately 10 million individuals 
are thought to be infected with the Tuberculosis bacterium 
in South Africa and the annual notification rate from 1981-
1985 in the city of Cape Town (the region of highest 
incidence in South Africa) was 312-370 per 100 000 
population (5,6). Notification rates in the developed 
countries are also on the increase as a direct result of the 
AIDS pandemic (Fig.1.1). This has resulted in a renewed 
demand for basic and clinical research in tuberculosis 
(2,3). Additional interest in the field of tuberculosis 
research has recently been generated by intriguing 
observations linking mycobacteria and autoimmunity (7). 
1.2. THE IMMUNE RESPONSE TO INFECTION WITH MYCOBACTERIA 
1.2.1. THE PATHOGENESIS OF TUBERCULOSIS 
The hallmark of Tuberculosis is the formation of caseating 
granulomata. Lurie's fundamental studies with resistant and 
susceptible inbred rabbits have provided major insights into 
events leading up to granuloma formation (8). More recent 
advances have allowed clinical, histological, immunological 
and molecular correlates to be established (9). In Lurie's 
studies, the number of human-type bacilli was quantitated in 
the lungs of naturally resistant and naturally susceptible 
1 
Fig. 1.1. Graph showing the number of reported cases of 
tuberculosis in the United States from 1981 to 1987. Those 
that are HIV-related are shown by the hatched area. 
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2 
rabbits after infection by quantitative airborne inhalation. 
On the basis of observations made during these studies, the 
pathogenesis of tuberculosis can be divided into four 
stages. 
1.2.1.1. The First Stage 
The first stage begins after the inhalation of the tubercle 
bacillus. An alveolar macrophage ingests the bacillus and 
often destroys it. This destruction depends on the inherent 
microbicidal power of the macrophage and the genetic and 
phenotypic virulence of the ingested bacillus. The 
microbicidal power of the alveolar macrophage is under 
genetic control and is also determined by its state of 
activation (10). Alveolar macrophages can be non-
specifically activated by a variety of inhaled particles and 
their microbicidal power therefore exists before the 
inhalation of Tubercle bacilli. Specific T cell mediated 
immunity is therefore not required at this level of 
resistance. 
1.2.1.2. The Second Stage 
3 
If the original alveolar macrophage fails to destroy or 
inhibit the inhaled bacteria, a symbiotic stage ensues. This 
stage is characterized by the logarithmic growth of bacilli 
and begins between 7 and 21 days after infection. Many blood 
borne macrophages enter the lesion. Histologically, 
macrophages of susceptible hosts contain more bacilli and 
are located in the alveoli. Macrophages in the lesions of 
the resistant host contain fewer bacilli and are usually 
located interstitially. Interestingly, these histological 
differences have no apparent effect on bacillary growth as 
the rate of bacterial multiplication is the same in 
resistant or susceptible rabbits. Macrophages in both types 
of host do not appear to be significantly microbicidal at 
this stage and are not activated as they are usually B-
galactosidase (a histo-chemical marker of macrophage 
activation) negative. It is evident therefore that the 
cytoplasm of blood-borne macrophages from both resistant and 
susceptible rabbi ts support bacillary growth equally well. 
This can be explained by the observation that genetic 
resistance to the tubercle bacillus is expressed only in 
activated macrophages (10). 
1.2.1.3. The Third Stage 
4 
The third stage of the disease begins when the logarithmic 
bacillary growth stops abruptly. At this stage, 
approximately 2 to 3 weeks after inhalation of the bacilli, 
the host possesses cell mediated immunity. When the second 
stage ends, the lungs of susceptible rabbits contain 20-30 
times more bacilli than do the lungs of resistant animals. 
In spite of the differences in bacterial load and inherent 
microbicidal power of the macrophages, the susceptible hosts 
inhibit bacillary growth as efficiently as the resistant 
hosts (8). Clearly, therefore, another mechanism must exist. 
This is evident from tissue sections of the lesions. The 
logarithmic growth stops as soon as caseous necrosis 
develops. A tubercle forms with a solid caseous center 
within which the now extracellular bacilli cannot multiply. 
Around this center, immature macrophages permit 
intracellular bacillary multiplication, but mature activated 
macrophages (produced by T lymphocyte and macrophage 
interaction) inhibit such multiplication. The tubercle 
bacillus can survive for years in this solid caseous 
material, but it cannot multiply due to the anoxic 
conditions, reduced pH and the presence of inhibitory fatty 
acids (11). Caseous necrosis appears to be mediated chiefly 
by cytotoxic T cells (12). Other factors including cytokines 
[particularly tumor necrosis factor (TNF)], reactive oxygen 
and nitrogen intermediates also seem to be involved (13,14). 
The stationary phase of bacillary growth lasts at least 8 
weeks. The difference 
the subsequent course 
rabbits, the lesion 
in macrophage activation 
of the disease. In the 




microbicidal macrophages. The bacilli that escape the 
caseous center are therefore ingested and destroyed. The 
tubercle becomes walled off, the caseous center inspissates 
and the disease is arrested, frequently for a lifetime. In 
the susceptible rabbits, the lesion is surrounded by many 
poorly activated macrophages, which still permit the 
bacillus to grow intracellularly ( 8, 15). These macrophages 
die and the caseous center enlarges. With virulent bovine-
type bacilli in susceptible rabbits, bacilli lodging in the 
draining tracheobronchial lymph nodes and elsewhere in the 
body are not destroyed. Multiple uncontrolled tubercles 
with extensive caseation form throughout the body, 
especially in the lungs, and the host may eventually die of 
the disease. With human-type bacilli, the disease in both 
strains of rabbits healed after many months. However, before 
such healing could take place, the susceptibles often 
developed metastatic haematogenous lesions while the 
resistants often developed cavities. 
1.2.1.4. The Fourth Stage 
Unfortunately, disease progression may occur even in 
resistant hosts. Such progression is caused by liquefaction 
and cavity formation (the fourth stage) (8,11,15-17). The 
factors that cause liquefaction are largely unknown ( 9) . 
Hydrolytic enzymes and TNF may be involved ( 9, 13). 
Characteristically, liquefied caseous foci and cavities do 
not occur in susceptible animals and are not common in 
infants and immunocompromised individuals ( 8, 15). It thus 
appears that an intact cell mediated immune response is a 
pre-requisite for this stage. The liquefied material is an 
excellent growth medium for the bacilli. For the first time 
5 
they multiply extracellularly, often reaching tremendous 
numbers (9). A large antigenic load is produced that is rich 
in tuberculin-like bacillary products (9). Since these 
products are toxic to the tissues of the tuberculin-positive 
host, the walls of nearby bronchi often become necrotic and 
rupture, forming the cavity. The bacilli are then discharged 
into the airways, thereby reaching other parts of the lung, 
as well as the outside environment. Liquefaction therefore 
perpetuates the disease. Another consequence of the large 
numbers of bacilli is that antibiotic-resistant mutants may 
arise (9). 
The progress of the disease in humans closely resembles that 
in rabbits (8,11,15-17). Significant differences do however 
exist, particularly with regard to the microbicidal power of 
macrophages, and aspects of these are detailed below. 
1.2.2. T-MONOCYTE INTERACTION AND MACROPHAGE MEDIATED PROTECTION 
6 
Intracellular bacteria including the etiologic agents of 
tuberculosis, Mycobacterium tuberculosis (M. tuberculosis) 
and Mycobacterium bovis (M. bovis), are capable of surviving 
inside professional phagocytes ( 18). In this way they are 
well shielded from humeral defence mechanisms. It is thought 
that during their intracellular lives, mycobacteria produce 
molecules which are processed and presented in the context 
of major histocompatibility complex (MHC) products on the 
surface of infected macrophages (18). In this way host cells 
infected with mycobacteria are recognized by T lymphocytes. 
The importance of T lymphocytes in host defence has been 
established beyond doubt in both in-vivo and in-vitro 
studies ( 19-25). T lymphocytes interacting with infected 
host cells become activated and, in turn, produce cytokines 
which function to activate both T lymphocytes and 
macrophages (18). Interferon-gamma (IFN-~) is thought to be 
the most important macrophage activating factor (26-28). In 
man an additional pathway involving vitamin D3 further 
amplifies macrophage activation (29). Thus when human (but 
not murine) macrophages are exposed to IFN-~ they develop a 
1-hydroxylase which converts the circulating inactive form 
of vitamin D3 ( 25-0H cholecalciferol) into the active 1-










( 2 8 , 3 0 , 31 ) . The 
situation with human monocytes and alveolar macrophages is 
much less convincing (30-34). Human macrophages stimulated 
with IFN-6 and calcitriol show increased resistance to M. 
tuberculosis (35,36). M. tuberculosis and M. avium-
intracellulare have however been shown to exhibit in-vitro 
resistance to the antimicrobial effects of IFN-'6 treated 
human macrophages (31,33,34). In addition, studies have 
shown that IFN-~ may accelerate the growth of mycobacteria 
in human macrophages ( 30, 37). In view of these equivocal 
observations, alternative mechanisms of protection are being 
investigated. Cytolysis of parasitized macrophages by 
specific T cells is an alternative mechanism, increasingly 
being considered, responsible for protection against 
mycobacterial infection (12). 
1.2.3. CYTOLYTIC T CELLS IN MYCOBACTERIAL INFECTION 
The hypothesis that cytolytic T cells (CTL) are an important 
effector mechanism is an attractive one. Lysis of 
parasitized host cells could have a number of either 
advantages or destructive consequences (Fig.1.2). Mere 
destruction of the cellular habitat may already be harmful 
to the microbe by exposing them to humeral effector 
mechanisms. Existence outside the cell may also be more 
difficult due to the possibility of dissolution by lysosomal 
enzymes ( 12). Also, lysis of infected host cells with low 
antimicrobial potential allows microbial transmission from a 
7 
Fig. 1.2. Possible consequences of T cell-macrophage 
interactions in intracellular bacteria). infections. 
(Reproduced from reference 74) 
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8 
protective niche to a more aggressive cell. Natural killer 
cells and lymphokine activated killer cells may also be able 
to kill the microbes directly (38-40). Destruction of 
parasitized macrophages could also minimize suppression 
since monocytes have been strongly implicated in this regard 
(1,41,42). It is also possible that destruction of infected 
host cells could lead to downregulation of the immune 
response by reducing the potential for antigen presentation 
and T-monocyte interaction. 
Unfortunately, tissue destruction is an inevitable 
consequence of lysis. The stronger the immune response, and 
the more important and essential the target cell, the worse 
the consequences for the host (12). Another potentially 
destructive consequence of lysis is the threat of 
dissemination (12). Thus, secondary sites of the body may be 
colonized. 












mycobacterial infection has not been easy to demonstrate 
experimentally in humans. Only one study has demonstrated 
the presence of Purified Protein Derivative (PPD)-specific 
CTL using the conventional 4-hour chromium release assay 
(43). PPD-stimulated peripheral blood mononuclear cells 
( PBMC) were employed as effectors and targets were 
autologous PBMC labelled with PPD (43). Another study could 
only demonstrate significant lysis, in a 16-hour chromium 
release assay, when PPD was coupled to targets with the 
plant lectin Concanavalin A ( 44, 45) . No significant lysis 
was observed against targets labelled with PPD alone (44). 
Autologous Ebstein Barr virus transformed lines were used as 
targets. The low levels of kill observed in that study may 
have reflected an intrinsic property of the specific helper 
T cell clones employed as effectors (44). More recent 
studies have been able to demonstrate lysis more readily by 
employing autologous adherent cell targets in 15-hour 
chromium release assays (46-48). All of these studies have 
demonstrated CD4 mediated MHC class II restricted lysis (46-
48). Ul trastructural analysis of lesions in patients with 
leprosy has provided in-vivo evidence of lysis occurring at 
the site of the pathology (46). Similar evidence in 
tuberculosis has not been described to date. 
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It is now generally accepted that there are two distinct 
pathways of antigen processing and presentation (49-52). 
Exogenously introduced soluble proteins are presented by MHC 
class II molecules and endogenously synthesized antigens are 
presented by MHC class I molecules ( 49, 51, Fig .1. 3). The 
main functional distinction between the two MHC classes is 
that class I molecules interact with cos+ cytolytic cells 
and class II molecules interact with CD4+ T cells with 
either helper or cytolytic function. Expression of MHC class 
II molecules, however, is restricted to certain cells with 
specialized antigen presenting functions, whereas virtually 
all other host cells express MHC class I molecules (52). It 
follows, therefore, that cos+ cytolytic T cells are likely 
to be required for lysis of most infected parenchyrnal host 
cells. Also, adoptive transfer experiments in mice have 
provided evidence implicating Lyt 2+, class I restricted 
cells in protective immunity (24). Despite these theoretical 
arguments implicating a role for cos+ cytolytic T cells, 
supporting experimental evidence has not been produced in 
humans (12,53). Such evidence is only available in in-vitro 
murine studies utilizing Lyt-2+ clones as effectors and bone 
marrow macrophages as targets (54). 
The failure to demonstrate cytolytic activity mediated by 
cos+ cells in humans may be due to the inability to generate 
antigenic peptides able to enter the class I pathway of 
antigen processing. Exogenously added soluble protein 
Fig. 1.3. Intracellular traffic and antigen processing. 
Different shadings have been used to represent MHC class I 
and class II molecules (black), invariant chain (white), 
exogenous antigen and fragments thereof (hatched), and 
endogenous antigen and fragments thereof (dotted). All 
elements are drawn schematically without any implication on 
their exact molecular structure. 
(Reproduced from reference 52) 
Class I Class 11 
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usually only enters the class II pathway of antigen 
presentation (52). The activation of ens+ CTL, however, 
requires antigen to be presented in the context of MHC class 
I (55). Recently it has been shown that soluble protein can 
be made to enter into the class I pathway of antigen 
presentation by the introduction of antigen directly into 
the cytoplasm of antigen presenting cells (55). EL4, a class 
II negative tumor target, was efficiently lysed by class!-
restricted ovalbumin-specif ic CTL only after the 
introduction of antigen directly into the cytoplasm by 
osmotic lysis of pinocytic vesicles containing native 
ovalbumin (55). Similar results were obtained with CNBr 
digests of native ovalbumin (55). No lysis was observed when 
EL4 was labelled with either native or tryptic digests of 
ovalbumin ( 55). These data suggest that the form of the 
endocytosed antigen and its subcellular localization 
determine MHC class I versus class II presentation (55). 
1. 2. 4. CYTOKINES AND TISSUE DAMAGE 
The role of cytokines (particularly TNF) in tissue damage 
has been well documented in the necrotic response to 
intradermal challenge with antigens of M. Tuberculosis (13). 
Macrophages activated with IFN-~ and calcitriol show a high 
degree of priming for TNF release (29). In fact, macrophages 
obtained from alveolar lavage samples of tuberculosis 
patients spontaneously release TNF (56). M. tuberculosis is 
itself a potent trigger of cytokine release from primed 
macrophages (29). The major triggering molecule in M. 
tuberculosis, comparable in efficacy to LPS, is a 
phosphatidyl inositol mannoside known as Lipoarabinomannan 
(LAM) ( 57). M. tuberculosis not only triggers TNF release, 
but also renders its host's cells more sensitive to the 
toxicity of this cytokine, so that normally 
levels become detrimental to the host (13). 
protective 
The exact 
relationship of these observations which are characteristic 
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of the necrotizing skin response to the more slowly evolving 
caseous necrosis is not known (13). It is probable however 
that TNF plays a role in causing tissue damage in 
granulomatous lesions, particularly in Lurie's fourth stage 
where high bacterial loads are characteristic. 
1. 2. 5. IMMUNE SUPPRESSION 
Suppression of the cell 
to play a role in 
mediated immune response is thought 
the pathogenesis of tuberculosis 
T lymphocytes, Natural killer cells ( 1, 41, 4 2) . Monocytes, 
and serum have all been shown to exert suppressor influences 
on the immune response to tuberculosis (1,41,42,58-61). 
However, all of the studies demonstrating suppression 
utilized cells obtained from the peripheral blood 
(1,41,42,58-61). 
Age and poor nutritional status are also widely believed to 
negatively impact on the immune response to tuberculous 
infection (62-64.). A potential mechanism for the decreased 
resistance observed in the elderly has been provided by 
experimental evidence showing a loss of protective T cell 
function in aged mice infected with M. tuberculosis (62). 
1 • 2 • 6 . PURIFIED ANTIGENS 
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Characterization of the antigenic components of mycobacteria 
is essential for the understanding of the immune response in 
patients, and could provide the basis of both serodiagnostic 
and skin tests. The most useful antigens for such tests 
would be recognized by many patients, would not be present 
in other mycobacteria and would be preferably immunodominant 
antigens. Progress in this field has been hampered by the 
scarcity of purified antigens. At least for protein antigens 
this problem has been solved because recently recombinant 
DNA clones have been used to produce large quantities of 
pure mycobacterial protein antigens (65,66). Other 
techniques have also been employed to purify protein 
antigens. These include affinity chromatography and sodium 
dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-
PAGE) ( 66). 
1.2.6.1. The Recombinant 65 kDa Antigen of M. Bovis BCG 
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The 65 kDa antigen of M. Bovis BCG is an example of a 
recombinant antigen and is currently the focus of much 
research (67). It is a well characterized and strongly 
immunogenic protein capable of eliciting antibody and T cell 
responses in infected patients (47,48,53,66-70). Studies in 
mice immunized with M. tuberculosis have demonstrated that 
20% of the mycobacteria-reactive T lymphocytes recognize 
this molecule ( 71). Amino acid sequence determination has 
revealed that the 65 kDa antigen is identical in M. bovis 
and M. tuberculosis, and highly homologous to the Eschericia 
coli heat shock protein (HSP) (71). The 65 kDa protein is, 
therefore, a HSP itself. The human homologue has also been 
found to be 50% identical with the mycobacterial antigen 
(72). The HSP are specific proteins produced by cells 
exposed to a variety of stress stimuli such as elevated 
temperature, nutrient deficiency, low oxygen pressure, pH 
alterations, viral infections and reactive oxygen metabolite 
attack (73). The HSP induce thermotolerance, protect cells 
from oxidative and other types of injuries, act as molecular 
chaperones for proteins, and may also play an important role 
in antigen processing (73). 
The 65 kDa antigen has been paradoxically implicated both in 
the pathogenesis of, and protection against, the development 
of autoimmunity (47-48,72-77). Lewis rats immunized with 
heat killed mycobacteria develop a rapidly destructive form 
of arthritis called adjuvant arthritis. The histological 
features of this disease resembles rheumatoid arthritis 
(78). The autoimmune nature of the disease was suggested by 
the observation that the disease could be transferred by T 
lymphocytes (79). These arthritogenic lymphocytes recognize 
a specific epitope present on the 65 kDa antigen ( 76). A 
similar epi tope has been found in joint cartilage, 
suggesting that autoimmune arthritis may be the result of a 
cross reaction between microbial antigen and host tissue 
( 80, 81). Like adjuvant arthritis rats, patients suffering 
from rheumatoid arthritis demonstrate specific T- lymphocyte 
reactivity to the M. tuberculosis fraction containing the 
cross-reactive epitope (82). 
On the other hand, vaccination with the 65 kDa antigen has 
been shown to induce resistance to the development of 
adjuvant arthritis in Lewis rats (76). Resistance was also 
shown to be dependent on T cell clones able to recognize the 
same epitope, as that recognized by arthritogenic clones, on 
the 65 kDa antigen (76). Similarly, streptococcal cell wall-
induced arthritis (a T cell dependent chronic, erosive 
polyarthritis can be prevented by pretreatment of rats 
with the 65 kDa antigen (77). 
Additional evidence that the 65 kDa antigen may be involved 
in destructive immune responses has recently come to light 
(47,48). Recombinant 65 kDa stimulated effector cells were 
shown to efficiently lyse autologous monocytes in the 
absence of antigen (47,48). More recent studies have 
provided a potential mechanism for this phenomenon ( 74). 
Bone marrow macrophages II stressed II by exposure to IFN-'t>, 
have been shown to express endogenous proteins bearing cross 
reactive epitopes to the recombinant 65 kDa antigen ( 74). 
These self epitopes are thus capable of sensitizing 
macrophages for lysis by autologous recombinant 65 kDa 
primed effector CTL. 
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The 65 kDa antigen has also been considered a potential 
candidate for a subunit vaccine (47). Doubt about its 
widespread application in this regard arose when a study 
showed that only 20% of 47 BCG responsive individuals (21 
healthy contacts and 26 patients with Leprosy) demonstrated 
significant responses to the 65 kDa antigen (47). However, 
the study described above (and most other studies involving 
the 65 kDa antigen) have assessed immune responses to this 
antigen at the clonal level and in peripheral blood (53,66-
70). Responses by cells obtained from the site of the 
pathology are likely to be more relevant in this regard. 
1.2.6.2. The 36 kDa and 65 kDa proteins of M. Leprae 
These antigens have been purified by either SOS-PAGE or 
affinity chromatography and screened with a battery of T 
cell clones and antibodies ( 66). The 36 kDa antigen was 
selected for study since it is one of the few antigens which 
contains a B cell epitope specific for M. Leprae. It has in 
fact already been used in a serodiagnostic test ( 83). M. 
Leprae specific epitopes have also been defined by T cell 
clones on both antigens. Interestingly, the antigens 
isolated from the bacilli contain more epi topes than the 
corresponding recombinant proteins (66). The most likely 
explanation for this phenomenon is that additional 
components are associated with the protein antigens even 
under the denaturing conditions in SOS-PAGE (66). 
The 65 kDa protein of M. Leprae has been extensively 
characterized and 24 T cell epitopes have been documented on 
this protein to date (84). All have been shown to be major 
histocompatibility complex (MHC) class II restricted (84). 
Almost all are HLA DR restricted (84). Thus immunity to the 
65 kDa protein is under strict class II immune response gene 
control. Furthermore, a correlation between specific 
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peptide, MHC class II and specific T cell receptor has been 
demonstrated (84). These correlations were noted to be 
specific to individuals (84). These observations have 
important implications for vaccine development. Thus future 
vaccines will have to contain a peptide recognized by most 
individuals or possibly more than one peptide to account for 
individual differences in antigen processing. 
1. 2. 7. GAMMA-DELTA T CELLS 
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Although most T cells express the alpha-beta receptor 
heterodimer, a small percentage of thymocytes and peripheral 
blood lymphocytes have been shown to express an alternative 
receptor known as the gamma-delta receptor (85), While the 
functions of T lymphocytes expressing the conventional 
alpha-beta receptor have been extensively studied, gamma-
delta T cells represent a subset with an as yet uncertain 
role. In the last few years some clues have emerged 
pertaining to a possible function for these cells. The first 
of these was the observation that gamma-delta cells show 
non-specific cytotoxicity (86). The second was that gamma-
delta T cells show site specificity. Non circulating 
lymphocytes found within murine skin and gut are largely 
composed of gamma-delta cells (87,88). In addition the 
gamma-delta receptors born by these cells appear to be 
highly restricted despite significant germline diversity. 
( 87, 88). Thirdly, gamma-delta T cells mature in the fetal 
thymus prior to alpha-beta cells (89). Thus the implication 
arising from these observations is that these cells may 
represent a first line of defence and are therefore found at 
sites where foreign invaders would most likely intrude first 
(90). Consistent with these notions was the observation that 
gamma-delta T cells were greatly increased in the draining 
nodes of mice after primary immunization with Mycobacterium 
tuberculosis ( 91). Analysis of cell cycle, interleukin-2 
receptor expression and of interleukin-2 responsiveness 
showed that a large proportion of these cells were activated 
in-vivo ( 91) . Significantly, the gamma-delta T cell 
population showed virtually no expansion after secondary 
immunization (91). 
Experiments with gamma-delta hybridomas isolated from an 
antigen-unselected population of neonatal thymocytes have 
resulted in intriguing observations further clarifying the 
antigen reactivity of these cells (90). More than a third of 
the hybridomas were found to spontaneously produce 
interleukin-2 (90). Of several antigens tested, the hybrids 
only responded to mycobacterial antigen ( 90). Strikingly, 
the PPD responsive hybrids were precisely those that produce 
interleukin-2 spontaneously (90). Further testing of the PPD 
responsive hybrids showed that most of them responded to the 
recombinant 65 kDa protein of M. Bovis BCG (90). These data 
therefore imply that at least a significant fraction of 
gamma-delta T cells are specialized to recognize epitopes on 
a class of phylogenetically conserved stress proteins or HSP 
which have previously been implicated as immunodominant 
mycobacterial antigens (92). 
1 . 2 . 8 . IMMUNOTHERAPY 
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Recent evidence has suggested that the immune reactions 
responsible for protection in tuberculosis are distinct from 
those contributing to the pathogenesis of the disease 
(9,13). Furthermore, pre-immunization of mice with 
mycobacterial antigen, so that delayed hypersensitivity is 
enhanced, has been shown to either greatly increase 
susceptibility of the skin challenge site to TNF or to lead 
to a complete loss of such sensitivity (13). The nature of 
the response was determined by the nature of the antigen. 
Thus mice pre-immunized with subcutaneous sonicated M. 
Vaccae in Complete Freund's adjuvant (CFA) rendered delayed 
hypersensitivity sites TNF insensitive while pre-
immunization with either M. Vaccae or CFA alone resulted in 
extreme TNF sensitivity (13). These observations have been 
extended to patients and preliminary data are encouraging 
( 93-96). Subcutaneous injections of 109 irradiation-killed 
M. vaccae into tuberculosis and leprosy patients resulted in 
restoration of immune recognition of common mycobacterial 
antigens and a reduction in the necrotic component of the 
tuberculin test without causing harmful side effects (94). 
Significant weight gain has also been noted in treated 
patients when compared to those not receiving immunotherapy 
(94). More recently, it has been shown that patients 
vaccinated with M. Vaccae, which had been subjected to 
various modifications, showed enhanced and probably 
beneficial alterations in immunological activity around 
pulmonary lesions resulting in closure of cavities ( 9 5) . 
This study also indicated that the immunotherapeutic agent 
is open to potentially beneficial modifications. Thus much 
more work is required and elucidation of the mechanism of 
immunotherapy at the cellular and molecular level might lead 
to a considerable refinement of what is, at present, a 
somewhat empirical approach (96). 
1.3. PERSISTING IMMUNE PHENOMENA IN TUBERCULOSIS 
At least three abnormalities that accompany tuberculosis are 
known to be inexplicably persistent. Necrotizing skin-test 
responsiveness can persist for years following tuberculosis 
(97). Also, a change in the pattern of glycosylation of the 
Fe portion of IgG (agalactosyl IgG) has been found to remain 
grossly abnormal in most tuberculosis patients long after 
clinical cure (98). Recently, alveolar macrophages obtained 
by bronchoalveolar lavage, from a patient with tuberculosis, 
were shown to actively synthesize l,25(0H)2D3 ten months 
after successful antituberculous therapy (99). The continued 
capacity to produce l,25(0H)2D3 was associated with a 
persistent lymphocytic alveolitis, in spite of the patient's 
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apparent clinical recovery ( 99). No evidence of M. 
tuberculosis could be found in direct smears and cultures of 
sputum, and bronchial aspirates were also negative ( 99). 
These authors considered that the persistent alveolitis was 
due to an ongoing inflammatory and immune response in the 
absence of M. tuberculosis (99). Others have, however, not 
ruled out the possibility that persistent mycobacterial 
components were causing the alveolitis (98). 
1.4. LONG TERM ANTIGEN PERSISTENCE 
1.4.1. ANIMAL STUDIES 
The evidence indicating that antigen can persist for months 
or years in the spleens and draining lymph nodes of 
immunized animals is persuasive and has been extensively 
reviewed ( 100). Studies employing even readily degradable 
radio-iodinated protein antigens such as human serum albumin 
have confirmed long term antigen retention ( 100). These 
studies have also precisely localized long term retained 
antigen to the processes of follicular dendritic cells found 
in the draining lymph nodes of immunized mice (100). It is 
thought that persisting antigen at this site plays an 
important role in the maintenance and regulation of the 
humeral immune response (101). 
L 4. 2. CLINICAL EVIDENCE OF LONG TERM ANTIGEN PERSISTENCE 
Persisting antigen has been implicated in the pathogenesis 
of a number of chronic diseases (102-104). 
Recently, putative persisting Yersinia antigen was 
demonstrated (by immunofluorescence and western blotting) in 
synovial-fluid cells obtained from patients with reactive 
arthritis (102). Extensive bacterial cultures were negative. 
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In one case, the antigen was detected 17 years after initial 
infection with Yersinia (102). However, the possibility that 
the specific anti-Yersinia antibodies used to detect the 
Yersinia antigen, was cross-reacting with a self epitope 
cannot be ruled out (102). 
Lyme borreliosis is a multisystemic infectious disease 
caused by the spirochete Borrelia burgdorferi. Antigen 
persistence is thought to be the most likely pathogenetic 
mechanism of Lyme disease (104). Limiting dilution analysis 
of peripheral blood lymphocytes from patients with chronic 
Lyme arthritis, have shown both an increased precursor 
frequency of cells reactive with Borrelia antigen, as well 
as a high proportion ( 23-100%) of in-vivo activated cells 
(104). Surprisingly, limiting dilution analysis of these 
cells 6 to 16 months after apparent clinical cure documented 
identical frequencies of in-vivo activated cells (104). 
Since the patients were asymptomatic, these observations may 
be the result of persisting antigen. Alternatively, anti-
idiotypic interactions via antigen receptors may be 
responsible for the maintenance of the activated Borrelia-
reactive T cells (104). 
1.5. SPONTANEOUS LYMPHOCYTE PROLIFERATION 
Spontaneous lymphocyte proliferation has not, prior to this 
work, been described in tuberculosis. The number of other 
diseases associated with this phenomenon, however, is 
mounting. It has been observed in Sarcoidosis, Rheumatoid 
arthritis and a number of viral infections ( 105-117). The 
phenomenon has also been observed in autoimmune MRL/Mp-
lpr/lpr mice (118-120). 
1. 5. 1. SARCOIDOSIS. 
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In this condition alveolar T lymphocytes obtained from 
patients with high intensity alveolitis were observed to 
proliferate and produce interleukin-2 ( IL-2) spontaneously 
(105,106). The proliferation was observed in both fresh 
unseparated mononuclear cells and purified T lymphocytes 
(105,106) cultured for 24 hours. These findings were 
restricted to alveolar lymphocytes and could not be 
demonstrated in the peripheral blood (105,106). The 
proliferation could be abrogated with steroid therapy and 
was thought to account for the increased number of cells 
found at the site of the pathology in this disease 
(107,108). In these earlier studies the initiating mechanism 
was not identified (105,106). It was, however, postulated 
that either all the requisite signals for T cell activation 
were present in the alveolar structures in patients with 
sarcoidosis and high intensity alveolitis, or that the 
effector cell population in the lungs of these patients 
could release IL-2 without all the requisite signals. 
Evidence supporting the former possibility appeared in a 
later study (109). In that study alveolar macrophages were 
shown to possess an enhanced 
( 109). This finding hinted 
capacity to present antigen 
at the possibility that 
persisting foreign antigen may be responsible for the 
initiation of the phenomenon. 
1 . 5 . 2 . RHEUMATOID ARTHRITIS. 
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The phenomenon in this disease shares similarities with its 
counterpart in Sarcoidosis, namely IL-2 dependent 
spontaneous proliferation by short term cultured lymphocytes 
obtained from the site of the pathology ( 110). Peripheral 
blood lymphocytes, however, demonstrated enhanced 
proliferative responses to exogenous IL-2 in spite of having 
no significant increase in the classic activation markers 
such as HLA DR, Tac and Transferrin (110). The spontaneous 
proliferation was shown to be largely dependent on dendritic 
cells (110). It was therefore concluded that the phenomenon 
was the result of an autologous mixed lymphocyte reaction 
(110). However, the presence of persisting foreign antigen 
in the dendritic cells was not excluded. 
1 . 5 . 3. VIRAL INFECTIONS. 
Spontaneous proliferation in the peripheral blood has been 
observed in Measles, Mumps and Rubella (111,112). It has 
also been observed in the early phases of in-vitro infection 
with human T cell leukemia virus types I and II (HTLV-I and 
-II) (121). The phenomenon has been most intensely studied 
in measles and HTLV infected patients (111,112,121). 
1.5.3.1. Measles 
Most of the serious complications of measles are due to 
secondary bacterial and viral infections causing pneumonia 
and diarrhoea, or to post-measles encephalomyelitis, an 
autoimmune demyelinating disease ( 113-116). Both types of 
complications, infectious and autoimmune, are thought to be 
related to the immunologic abnormalities that accompany 
acute measles (111,117). Peripheral blood lymphocyte 
activation and spontaneous proliferation is one such 
abnormality (111,112). In this disease, spontaneous 
prolif era ti on was noted in the peripheral blood to appear 
coincident with the onset of the rash and to persist for 
approximately 10 days (111,112). It was, therefore, thought 
that the spontaneous proliferation represented cells which 
were released into the peripheral blood from infected 
tissue, the primary site where cellular proliferation is 
induced by viral antigen and interleukin-2 (111). This 
release was thought to occur during vigorous phases of 
cellular expansion (111). 
1.5.3.2. Human T cell leukemia virus types I and II. 
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It is well recognized that HTLV-I and HTLV-II infection in-
vitro induces an early polyclonal T cell proliferation in-
vitro that is supplanted by a monoclonal, growth-factor 
independent outgrowth of leukemic cells (121). A viral gene 
and protein has been observed to activate interleukin-2 
genes, interleukin-2 receptor 





proliferation is thus thought to involve virus gene induced 
autocrine proliferation ( 121). The subsequent events that 
result in the emergence of a clonal growth factor 
independent leukemic T cell population remain undefined 
(121). 
1.5.4. SPONTANEOUS LYMPHOCYTE PROLIFERATION IN MRL/MP-LPR/LPR MICE. 
MRL/Mp-lpr/lpr mice develop an age dependent progressive 
lymphoproliferative disease, which is characterized by the 
massive accumulation of an unusual subset of lymphocytes in 
their lymphoid organs (118,119). These mice develop a rapid 
onset systemic lupus erythematosis-like syndrome 
characterized by autoantibody production (118,119). Lymph 
node T cells from these mice but not from congenic MRL/Mp-
+/+ have been shown to proliferate spontaneously when 
cultured in-vitro for 5 to 7 days ( 118). In contrast with 
the other conditions discussed above ( and similar to our 
observations in a 
freshly isolated 
subset of patients with tuberculosis), 
lymphocytes did not proliferate 
spontaneously (118). Spontaneous proliferation was only seen 
after 5 to 7 days of in-vitro culture (118). The length of 
in-vitro culture and initial culture density was shown to be 
critical, indicating that cell to cell interaction was 
essential for the initiation of the proliferation (118). The 
proliferation could be blocked by both anti-T4 and anti-IL-
2-receptor antibodies (118). This confirmed the phenomenon 
to be IL-2 dependent and, in addition, indicated that the 
proliferating cells were CD4+. An intriguing observation 
made in these studies was that the spontaneous proliferation 
and IL-2 production could be detected in young MRL/Mp-
lpr/lpr mice at a time when lymphoproliferation and 
autoimmunity were not obvious (118). The relationship 
between the spontaneous proliferation and the development of 
autoimmunity was not established in these studies. The cells 
involved in the spontaneous proliferation were shown to be 
CD4+ and therefore cannot be the abnormal T cells shown to 
accumulate in lpr/lpr mice since it is known that these 
abnormal T cells lack the CD4 marker (120). However, these 
authors speculate that the spontaneously proliferating 
lymphocytes may produce lymphokines that accelerate the 
growth of the abnormal T cells or enhance the polyclonal 
activation of B cells (resulting in autoantibody production) 
(118). 
1.6. CONCLUSION 
It is clear from the above review that cellular immune 
mechanisms play a prominent role after infection with M. 
Tuberculosis. This thesis therefore examines several aspects 
of the cellular immune response in tuberculosis in an 
attempt to further define protective immune responses. 
As discussed above, the development of caseation within 
granulomata has been shown to be associated with an abrupt 
end to mycobacterial multiplication. In-vitro evidence 
suggests that cell mediated cytotoxicity and/or cytokine 
release may result in caseation. In-vivo evidence for cell 
mediated cytotoxicity against macrophages infected with M. 
Tuberculosis is however lacking. Thus particular attention 
was paid to cell mediated cytolysis in patients with active 
tuberculosis. 
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Proliferation and cytotoxici ty to the recombinant 65 kDa 
antigen of M. Bovis BCG was also assessed in these patients 
because this antigen has been shown to be irnmunodominant in 
mice, is a HSP, and has been considered as a potential 
candidate for a vaccine. 
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CHAPTER 2 
DESCRIPTION OF A NOVEL IMMUNE PHENOMENON IN TUBERCULOSIS: 
PERSISTENT IN-VITRO SPONTANEOUS PERIPHERAL BLOOD LYMPHOCYTE 
PROLIFERATION 
2.1. ABSTRACT 
Spontaneous lymphocyte proliferation was noted in-vitro, in 
lymphocytes obtained from the peripheral blood of a subset 
of patients with tuberculosis. The proliferation persisted 
in some cases and was noted in one case four years after 
apparent clinical and radiological cure. Proliferation was 
assessed by 3[H]thymidine incorporation. Receptor studies, 
including immunostaining and blocking with anti-interleukin-
2-receptor antibody, indicated that the proliferation was 
mediated by the major T-cell lymphokine interleukin-2. 
Several levels of evidence implicated mycobacterial 
antigenic components in the initiation of the proliferation. 
Firstly,the kinetics of the proliferation resembled that of 
antigen-driven T cell proliferation. Secondly, the 
proliferation had a strict requirement for the presence of 
accessory cells, since: i) adherent cell depletion abrogated 
the phenomenon, ii) adherent cell supernatants obtained from 
patients with high spontaneous proliferation caused 
significant stimulation only when added to unseparated 
control cells obtained from a known PPD responder, and not 
when added to purified T cells obtained from the same 
control PPD responder. Thirdly, adherent cell supernatants 
obtained from control tuberculosis patients lacked 
stimulatory activity despite having detectable levels of 
thymocyte co-mi togenic activity. Taken together, the data 
suggests continuous secretion of antigenic mycobacterial 
components capable of stimulating T-cell proliferation in a 
subset of patients following infection with M. tuberculosis. 
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2.2. INTRODUCTION 
Lymphocytes plated in conventional in-vitro cultures do not 
usually proliferate unless stimulated with exogenous 
antigen. Spontaneous lymphocyte proliferation has however 
been observed in a number of disease states. These include 
sarcoidosis, rheumatoid arthritis and a number of viral 
infections (105,106,110-112). It has also been observed in 
an animal model of systemic lupus erythematosis (118,119). 
In the course of routinely assessing cellular immune 
responses in patients infected with M. tuberculosis, a 
subset of patients were observed to have spontaneous 
peripheral blood lymphocyte proliferation. The phenomenon 
was noted to persist in a number of these patients. 
At least three other abnormalities associated with 
tuberculosis have been shown to persist. Necrotizing skin 
test responsiveness may persist for years following 
tuberculosis (97). A change in the pattern of glycosylation 
of the Fe portion of IgG has been found to remain abnormal 
in most TB patients long after clinical cure ( 98). More 
recently, the serum levels of 1,25(0H)2D3 in a patient with 
TB was shown to peak nine months after the start of 
treatment, when the patient was clinically well (99). This 
patient still had an active alveolitis at the time and 
lavage cells were found to be synthesizing active 
metabolites (99). 
The mechanisms underlying these persisting phenomena are not 
fully understood. In this study, evidence suggesting that 
spontaneous lymphocyte proliferation in tuberculosis may be 
due to persisting mycobacterial components is provided. 
2.3. MATERIAL AND METHODS 
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2.3.1. Study population: Tuberculosis 
A total of 46 patients were studied. Active tuberculosis 
(TB) was diagnosed in 45 patients by the presence of acid 
fast bacilli in the sputum or biopsy specimen. Thirty four 
had pulmonary TB, four had nodal TB, three patients had 
disseminated disease, three had tuberculous pleuritis, and 
one had miliary TB. The remaining case had non-specific 
symptoms without evidence of overt disease. This patient had 
sputum positive pulmonary TB four years prior to inclusion 
in the study. Two patients had received treatment at the 
time they were first studied and one had intermittent 
courses prior to inclusion in the study. 
2.3.2. Study population: normals 
The 22 controls were all young laboratory staff and medical 
students. 
2.3.3. Isolation and separation of peripheral blood 
mononuclear cells 
Heparinised (thromboloquine, 250 units/15 ml blood, Organon 
Teknika 80701596, Boxtel, Holland) peripheral blood was 
separated by Ficoll-Hypaque density gradient centrifugation 
essentially as described (122). The blood was spun at 350G 
for 12 minutes. The huffy coat was removed, diluted with an 
equal volume of phosphate buffered saline (PBS) and overlaid 
on 3 ml of Ficoll-Hypaque in sterile plastic tubes (Falcon 
2025, Becton Dickinson, California, U.S.A.). The tubes were 
spun at 400G for 30 minutes and the interface was removed, 
diluted with PBS and the cells were pelleted by 
centrifugation. The peripheral blood mononuclear cells 
(PBMC) thus obtained were washed 2 more times with PBS and 
utilized as unseparated PBMC or further fractionated as 
described below. 
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2.3.4. Spontaneous proliferation of PBMC 
Freshly isolated unstimulated PBMC (1 x 105) were added to 
wells of 96 well round-bottomed sterile tissue culture 
plates (Flow Laboratories) in 0.2 ml of RPMI 1640 tissue 
culture media (Flow Laboratories, Irvine, Scotland) 
containing 10% pooled AB human serum, 100 u/ml penicillin 
and 100 mg/ml streptomycin (Gibco, Grand Island, N.Y.) 
hereafter referred to as complete medium. Control cells were 
in all cases plated at the same time in the same complete 
media. Autologous serum was used in place of pooled human 
serum in some cultures and some cultures also contained 
varying concentrations of either autologous or pooled human 
serum ranging from 10% to 30%. A prostaglandin inhibitor 
(indomethacin, Sigma 17378, Sigma-Aldrich Corporation, St. 
Louis, Missouri) was added to some cultures at 
concentrations ranging from 2% to 0.25%. The cultures were 
incubated at 37 °c in a humidified atmosphere containing 5% 
CO2. Tritiated thymidine (2 µCi/well, specific activity 185 
Mega BQ, Amersham 120, Amersham Laboratories, 
Buckinghamshire, England) was added to cultures on either 
day 3, day 6 or day 9 for an additional 16-18 hours. The 
cells were harvested using an automated harvester (Titertek 
630), and radioactivity was measured using a liquid 
scintillation counter (Packard, Tricarb 4640). All assays 
were performed in triplicate. Spontaneous proliferation was 
considered significant if> 3000 cpm (approximately the sum 
of the mean and 3 standard deviations of 22 control 
subjects). 
2.3.5. Quantification of IL-2 receptor and HLA-DR expression 
The IL-2 receptor was identified by using 100µ1 of the 
monoclonal antibody IL-2Rl (10 µg/ml, Coulter, Hialeah, 
Florida). L-243 ascites (124) was used to identify HLA-DR. 
Briefly, the relevant antibody was added to 1 x 106 cells 
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resuspended in 100µ1 at 4 °c for 45 minutes. The cells were 
washed 3 times with PBS containing 2.5% FCS and 0.02% sodium 
azide and 100µ1 of the appropriate dilution of a fluorescein 
iso-thiocyanate conjugated ( FITC) F (ab)' 2 goat anti-mouse 
(Cappel, Cooper Biomedical) immunoglobulin reagent was added 
to the cells at 4 °c for an additional 30 minutes. The cells 
were washed 3 times and examined by indirect fluorescence 
microscopy. At least 200 cells were counted for each sample. 
2.3.6. Effect of anti-IL-2 receptor antibody on spontaneous 
proliferation 
Anti-IL-2-receptor antibody (anti-Tac, a kind gift from Dr 
Waldman, NIH, Bethesda) was added to cultures at 5 and 10 
µg/ml and the effect on proliferation was assessed as 
described above. 
2.3. 7. Effect of adherent cell depletion 
PBMC were adhered to plastic petri dishes (Falcon, Becton 
Dickinson) for 45 minutes. The non adherent cells (NAC) were 
gently decanted. 1 x 105 NAC were plated in 0.2ml complete 
medium. Spontaneous lymphocyte proliferation was quantitated 
as described above. 
2.3.8. Identification of adherent cells 
Adherent cells were recovered following treatment with cold 
0.08% EDTA-PBS (BDH Chemicals Ltd, Poole, England) and 
incubated for a further 15 minutes at 370c. 1 x 106 
recovered cells were stained with the monocyte/macrophage 
marking monoclonal antibody MY4 (Coulter, Hialeah, Florida) 
followed by FITC and percent fluorescence was determined as 
described above. 
2.3.9. Effect of adding non-T (E-) to purified T cells (e-t-) 
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PBMC were rosetted using sheep red blood cells (SRBC) (123). 
SRBC-absorbed pooled AB human serum was prepared in advance. 
The human serum (HS) was absorbed, at a ratio of 2: 1, to 
washed SRBC for 1 hour at 37°c followed by an overnight 
incubation at 40c. The absorbed HS was filtered and stored 
at -2ooc until required. On the day of cell separation, 
fresh SRBC were washed 3 times and made up to 3% in 40% SRBC 
absorbed HS-PBS in a total volume of 10 ml. Unseparated PBMC 
were reconstituted at 5 x 106/ml in 10 ml of 40% HS-PBS. 
Equal volumes of cells in 40% HS-PBS and 3% SRBC-40% 
absorbed HS-PBS were mixed and underlaid with 15 ml Ficoll-
Hypaque in 50 ml sterile plastic tubes (Falcon 2025, Becton 
Dickinson, California, U.S.A.). The tubes were incubated for 
1 hour at 40c and then spun at 800G for 30 minutes. The non-
T cells contained in the interface were removed, washed 3 
times in 5% HS-PBS and resuspended in complete medium. The 
pellet containing the T cells bound to SRBC was resuspended 
in NH4Cl (0.77%) and incubated for approximately 5 minutes 
at 37°c until all SRBC were lysed when the reaction was 
stopped with cold PBS. The cells thus obtained were washed 3 
times with 5%HS-PBS and resuspended in complete medium. Each 
cell subset was plated in triplicate at 1 x 105 per well. To 
determine which cells were proliferating and what the 
requirements for activation were, non-T cells (5 x 104) were 
added back to 5 x 104 purified T cells and proliferation 
determined as described above. The non-T cells were 
irradiated (1000 rads) in some experiments, prior to 
addition to culture. 
2.3.10. Analysis of adherent cell supernatants 
Supernatants of adherent cells from patients with and 
without high spontaneous proliferation (and also control 
subjects) was obtained by adhering 2 x 106 unstimulated PBMC 
to sterile plastic petri dishes for 45 minutes. The NAC were 
decanted and the adherent cells were gently washed three 
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times. 1 ml of complete medium was added to the adherent 
cells and removed 24 hours later to be frozen at -20 °c 
until tested in the thymocyte co-mitogenesis assay as 
previously described (125). Briefly, the thymus gland of a 6 
week old BALB/ c mouse was aseptically removed and teased 
apart. The cells thus obtained were washed 3 times and 
resuspended in RPMI 1640 (Flow Laboratories, Irvine, 
Scotland) supplemented with 10% fetal calf serum (Gibco, 
011-6290, Gibco Middlesex, England) , 100 u/ml penicillin 
and 100 mg/ml streptomycin (Gibco, Grand Island, N.Y.). 
Thymocyte density was adjusted and 1 x 106 cells were placed 
in each well of a round-bottom microtitre plate (Flow 
Laboratories, Irvine, Scotland). In addition to the cells 
each well contained a submitogenic dose of 
phytohaemagglutinin (PHA) (HA 16, Welcome Diagnostics, 
Temple Hill, Dartford, England, a 1:400 dilution was found 
to be submitogenic in earlier assays) and the test 
supernatant or complete medium in a final volume of 200 µl. 
Supernatants obtained from control adherent cells cultured 
in the presence of E. coli Lipopolysaccharide (LPS, Difeo) 
served as positive controls. The cultures were incubated for 
72 hours and [3H]thymidine was added during the last 18 
hours. The cells were harvested and [3H]thymidine 
incorporation was determined as described above. Results 
were expressed as stimulation indeces. The stimulation index 
was calculated as follows: mean cpm in wells containing PHA 
and test supernatant/mean cpm in wells containing PHA and 
complete medium. A stimulation index of greater than 3 was 
considered a positive result. 
The capacity 
proliferation 
of these supernatants 
was also analyzed by adding 
to stimulate 
them to NAC 
obtained from patients with and without spontaneous 
lymphocyte proliferation. In addition, the supernatants were 
added to control cells obtained from a known normal PPD 
responder, both in the presence and absence of antigen 
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presenting cells (APC). APC were removed from the control 
cells by twice rosetting with SRBC followed by two cycles of 
plastic adherence. Proliferation was quantitated on day 6 as 
described above. 
2.3.11. Statistical analysis 
Confidence intervals were calculated as described (126). 
Analysis of variance by comparison of means was used to 
calculate P values. 
2.4. RESULTS 
2.4.1. Spontaneous lymphocyte proliferation in TB 
In-vitro cultured unstimulated PBMC from 6 of 46 patients 
showed high spontaneous lymphocyte proliferation when 
compared to the normal controls (Fig.2.1). The proliferation 
was statistically significant in all 6 cases ( P < 0. 01). 
None of the cells obtained from normal individuals 
manifested the phenomenon 
similar to that of the 
and their proliferation was 
remaining 40 patients with 
tuberculosis (Fig.2.1) (Mean difference 284, 95% confidence 
interval (CI) -20 to 588; t = 2.0, degrees of freedom (df) = 
60, P > 0.05). Plating on different areas of the same plate 
and also simultaneously on separate plates reproduced the 
phenomenon consistently. Parallel cultures comparing pooled 
human serum and autologous serum yielded identical results 
(Table 2 .1). The proliferation was also not influenced by 
the prostaglandin inhibitor indomethacin (Table 2.2). 
2.4.2. Spontaneous proliferation over time 
In one case (Fig.2.2.1), the phenomenon persisted for 13 
months and possibly longer, since the patient was lost to 
Fig. 2.1. Spontaneous lymphocyte proliferation in patients 
with TB compared to normals. Unstimulated PBMC, 105 ,from 46 
TB patients and 22 controls were cultured for 6 days and 
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Table 2.1. Spontaneous lymphocyte proliferation in 
autologous serum compared to pooled human serum. 
PATIENT PERCENT HS* POOLED HS AUTOLOGOUS HS 
------------------------------------------------------------
1 10% 72936 + 19765 68737 + 35567 
20% 56071 + 15630 47298 + 15114 
30% 59292 + 2270 48789 + 4315 
2 10% 67809 + 243 110011 + 25822 -
20% 100909 + 10568 89698 + 545 
Unstimulated PBMC were cultured for 6 days in RPMI 
supplemented with varying concentrations of either pooled 
human or autologous serum. Each culture was pulsed with 
(3H]thymidine for the last 16-18 hours. Values are mean cpm 
+SD.Data represent the means of triplicate determinations. 
*HS, human serum 
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Table 2.2. Effect of the prostaglandin inhibitor 
indomethacin on spontaneous lymphocyte proliferation. 
PATIENT % INDOMETHACIN MEAN CPM + SD 
------------------------------------------------------
1 2% 14344 + 1684 
1% 13728 + 2988 
0.5% 13232 + 2100 
0.25% 9400 + 557 
0% 13332 + 1357 
2 2% 38935 + 16012 
1% 46976 + 11419 
0.5% 49079 + 6629 
0.25% 46686 + 17980 
0% 46059 + 4785 
Unstimulated PBMC were cultured for 6 days in complete 
medium. A prostaglandin inhibitor was added at the doses 
shown. Each culture was pulsed with [3H]thymidine for the 
last 16-18 hours. Values are mean cpm +SD.Data represent 
the means of triplicate determinations. 
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Fig. 2.2.1. Spontaneous lymphocyte proliferation over time 
(Patient 1). Unstimulated PBMC were cultured for 6 days and 
pulsed with [3H]thymidine for the last 16-18 hours. This was 
































Feb Mar Mar Mar 
1987 





until the eighteenth month when spontaneous 
proliferation was no longer present. In this 
patient the abnormality persisted at least 4 months after 
complete clinical and radiological resolution of disease. 
The proliferation persisted for the duration of the follow 
up period (4 months) in a second case (Fig.2.2.2). No 
decrease in the level of proliferation was detected in this 
patient in spite of gradual clinical improvement. The 
proliferation persisted for 14 months in a third case 
without any clinical or radiological evidence of disease 
activity (Fig. 2. 2. 3) and was transient in two cases. The 
sixth patient was lost to follow up and no longitudinal data 
is available. 
2.4.3. IL-2 receptor expression and blocking 
The spontaneously proliferating cells expressed IL-2 
receptors on day 6 (Table 2.3). IL-2 receptors were neither 
detected on fresh PBMC obtained from these patients (Table 
2.3) nor on day 6 control cells. Anti-IL-2 receptor antibody 
(anti-Tac) blocked the proliferation in a dose-dependent 
manner (Fig. 2 . 3 ) . In repeated experiments, the percentage 
reduction in proliferation ranged from 21 to 75% at Sµg/ml 
anti-Tac and from 30 to 87% at lOµg/ml anti-Tac. 
2.4.4. HLA-DR expression 
Expression of HLA-DR antigen was not significantly increased 
in fresh PBMC obtained from patients with spontaneous 
lymphocyte proliferation (Table 2.4). However, an increase 
in HLA-DR was observed, in cells obtained from patients with 
spontaneous proliferation after 6 days of unstimulated 
culture ( Table 2. 4 ) . Similar changes were not observed in 
normal control cells and cells obtained from patients 
without spontaneous proliferation (Table 2.4). 
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Fig. 2.2.2. Spontaneous lymphocyte proliferation over time 
(Patient 2), Unstimulated PBMC were cultured for 6 days and 
pulsed with [3H]thymidine for the last 16-18 hours. This was 
repeated at the time intervals indicated. 
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Fig. 2.2.3. Spontaneous lymphocyte proliferation over time 
(Patient 3). Unstimulated PBMC were cultured for 6 days and 
pulsed with [3H]thymidine for the last 16-18 hours. This was 
repeated at the time intervals indicated. 
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Table 2.3. Percent IL-2 receptor expression by PBMC obtained 














Unstimulated PBMC were cultured for 6 days and then stained 
for IL-2 receptor expression using indirect fluorescence. 
Data represent percentage of cells staining positive by 
indirect fluorescence microscopy. 
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Fig. 2.3. Blocking of spontaneous lymphocyte proliferation 
by anti-IL-2 receptor antibody. Anti-IL-2 receptor antibody 
was added to unstimulated PBMC at 5 and 10 µg/ml and 
proliferation assessed on day 6 by (3H]thymidine 
incorporation into DNA. 
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Table 2.4. HLA-DR expression by unstimulated PBMC obtained 
from TB patients and controls. 
PERCENT OF CELLS POSITIVE: 
EXPERIMENT DAY O DAY 6 
1 6 18 
2 11 25 
3 2 10 
4 14 3 
5 6 0 
6 21 0 
7 7 0 
8 4 0 
Results are expressed as percent positively staining cells 
as determined by indirect fluorescence microscopy. 
Experiments 1-3 were performed on cells obtained from 
patients with spontaneous lymphocyte proliferation. 
Experiments 4-6 were performed on cells obtained from 
patients without spontaneous lymphocyte proliferation. 
Experiments 7 and 8 were performed on cells obtained from 
control subjects. 
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2.4.5. Kinetics of spontaneous proliferation 
The kinetics of the proliferation resembled that of antigen 
driven proliferation with peak proliferation on day 6 of 
culture (Table 2.5). All cases demonstrated the same pattern 
of kinetics. 
2.4.6. Effect of removing adherent cells 
Depleting the PBMC of adherent cells by plastic adherence 
almost completely abrogated the proliferation in 4 of 5 
patients tested (Table 2.6). By this relatively crude 
technique spontaneous proliferation could not be abrogated 
in only one patient (patient 5, Table 2.6). 
2.4. 7. Identification of adherent cells 
The percentage of adherent cells staining positive with the 
monocyte marker MY4 was 78%, 80% and 82% in 3 experiments 
respectively. This confirmed that the majority of the 
adherent cells were monocytes. 
2.4.8. Effect of adding back non-T (~) cells 
Adding back viable (Fig.2.4.1) or irradiated (Fig.2.4.2) 
non-T cells (E-) to autologous purified T cells (E+) 
reconstituted and augmented the proliferation. Similar 
treatment of control cells resulted in only low levels of 
proliferation, as shown in the figures. This confirmed the 
requirement for T/non-T cell interaction in the initiation 
of this phenomenon and that the proliferating cell was a T 
lymphocyte. 
2.4.9. Effect of adding adherent cell supernatants to non-
adherent cells 
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Table 2.5. Kinetics of spontaneous lymphocyte proliferation. 
PATIENT DAY 3 DAY 6 DAY 9 
----------------------------------------------------------
1 2240 + 403 26842 + 6554 2271 + 1633 -
2 18946 + 294 39102 + 2890 ND* 
3 2363 + 355 169763 + 30474 ND 
4 23406 + 1300 106051 + 2913 ND 
5 4810 + 382 16417 + 5940 ND 
6 2584 + 1010 121730 + 18433 34486 + 1386 
Unstimulated PBMC were cultured for 3, 6 and 9 days in 
complete medium. Each culture was pulsed with [3H]thymidine 
for the last 16-18 hours. Values are mean cpm + SD. Data 
represent the means of triplicate determinations. 
*ND, not done. 
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Table 2.6. Effect of adherent cell depletion. 
PATIENT us PBMC+ NAC 
--------------------------------------------------
1 161432 + 15024 518 + 29 
2 106051 + 2914 451 + 111 
3 48704 + 1595 1105 + 577 
4 169763 + 30474 392 + 305 
5 54688 + 3074 55733 + 2432 
NAC or unseparated PBMC (1 x 105/well) were cultured without 
addition of antigen 
complete medium. To 
in 96 well tissue culture plates 
obtain NAC, PBMC were incubated 
in 
on 
plastic petri dishes for 45 minutes after which NAC were 
decanted and collected. Values are mean cpm + SD. Data 
represent the means of triplicate determinations. 
+us PBMC, Unseparated peripheral blood mononuclear cells. 
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Fig. 2.4.1. Effect of adding back non-T (E- ) cells to 
purified T (E+) cells. PBMC were rosetted using SRBC. 
105/well each of unseparated (US), non-T (N) and purified T 
cells (T) were cultured in parallel. 5 x 104 non-T cells 
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Fig. 2.4.2. Effect of adding back non-T (E- ) cells to 
purified T (E+) cells. PBMC were rosetted using SRBC. 
105/well each of unseparated (US), non-T (N) and purified T 
cells (T) were cultured in parallel. 5 x 104 non-T cells 
were added back to 5 x 104 purified T cells. 
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Addition of adherent cell supernatants obtained from 
patients with high spontaneous proliferation to autologous 
NAC resulted in marked proliferation ( Table 2. 7. 1). 
Proliferation was not seen when these supernatants were 
added to NAC obtained from a normal individual (control 1 in 
Table 2. 7. 2). NAC from a TB patient without spontaneous 
proliferation also did not proliferate in response to the 
adherent cell supernatant (control 2 in Table 2.7.2). 
However, the adherent cell supernatant from one patient with 
high spontaneous proliferation caused the NAC from a second 
patient with the same phenomenon to proliferate (patient 2 
in Table 2.7.1). 
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2.4.10. Analysis of adherent cell supernatants in the 
thymocyte co-mitogenesis assay. 
Bioassay analysis of the supernatants demonstrated 
spontaneous thymocyte co-stimulatory activity in adherent 
cell supernatants obtained from patients with spontaneous 
proliferation (Table 2.8.1). However, some TB patients 
without spontaneous proliferation also demonstrated similar 
levels of spontaneous thymocyte co-stimulatory activity 
(Table 2.8.2). 
2.4.11. Effect of adding adherent cell supernatants to 
unseparated and purified T cells obtained from a known 
normal PPD responder 
Addition of adherent cell supernatants obtained from 
patients with high spontaneous proliferation to unseparated 
control cells obtained from a known PPD responder resulted 
in proliferation (Fig 2. 5). However, addition of the same 
supernatants to purified T cells obtained from the same 
control individual did not result in proliferation (Fig 
2.5). Adherent cell supernatants obtained from normal 
controls and TB patients without high spontaneous 
Table 2.7.1. Effect of adherent cell supernatants obtained 
from patients with spontaneous lymphocyte proliferation on 
autologous NAC and NAC obtained from other patients with 
spontaneous lymphocyte proliferation. 
TEST SUPERNATANT NON ADHERENT CELLS 
---------------- ------------------------------------
PAT.+1 PAT.2 PAT.3 
MEDIUM* 9193 + 1934 1175 + 343 392 + 306 
PAT.1 EXP. 1 108013 + 17393 ND# ND 
EXP. 2 111065 + 19560 ND ND 
PAT.2 23993 + 6592 23390 + 5932 ND 
PAT.3 ND ND 56845 + 3676 
Adherent cell supernatants were added 
Proliferation was assessed on day 6 
to 1 x 105 NAC. 
by [3H]thymidine 
incorporation. Values are mean cpm + SD. Data represent the 
means of triplicate determinations. 
*MEDIUM, RPM! supplemented with 10% pooled AB human serum. 
+PAT. , patient 
#No, not done. 
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Table 2.7.2. Effect of adherent cell supernatants obtained 
from patients with spontaneous lymphocyte proliferation on 
control NAC. 
TEST SUPERNATANT NON ADHERENT CELLS 
CONTROL 1 CONTROL 2 
MEDIUM* 7323 + 1191 345 + 25 
PAT.+1 EXP. 1 7331 + 1534 343 + 25 -
EXP. 2 4734 + 1091 ND# 
PAT.2 ND 434 + 116 
PAT.3 ND 394 + 84 
Adherent cell 
Proliferation 
supernatants were added 
was assessed on day 6 
to l x 105 NAC. 
by [3H]thymidine 
incorporation. Values are mean cpm +SD.Data represent the 
means of triplicate determinations. 
*MEDIUM, RPMI supplemented with 10% pooled AB human serum. 
+PAT. , patient 
#No, not done. 
52 
Table 2.8.1. Thymocyte co-mitogenic activity of unstimulated 
adherent cell supernatants obtained from patients with 
spontaneous lymphocyte proliferation. 
TEST 
SUPERNATANT MEAN CPM + SD 
A] MEDIUM 
MEDIUM+ PHA 
PAT. 1 + PHA 
PAT. 2 + PHA 




CYTE SUP. + PHA 
CONTROL MONOCYTE 
SUP.+ PHA 
1070 + 673 
960 + 436 
3897 + 300 
8518 + 1566 
2656 + 863 
691 + 138 
1555 + 443 
18604 + 2905 








Results are expressed as mean cpm + SD (3H]thymidine 
incorporation. Data represent the means of triplicate 
determinations. Stimulation indeces were calculated as 
follows: mean cpm in wells stimulated by test supernatant 
and PHA/mean cpm in wells containing medium and PHA. A 




Table 2. 8. 2. Thymocyte co-mitogenic activity of unstimulated 
adherent cell supernatants obtained from normals and 
patients without spontaneous lymphocyte proliferation. 
TEST STIMULATION 
SUPERNATANT MEAN CPM + SD INDEX 
-----------------------------------------------------
MEDIUM 1070 + 673 
MEDIUM+ PHA 960 + 436 
PAT. 1 + PHA 4634 + 1224 4.8 
PAT. 2 + PHA 4719 + 118 4.9 
PAT. 3 + PHA 2441 + 570 2.5 
PAT. 4 + PHA 761 + 303 0.8 
PAT. 5 + PHA 902 + 530 0.9 
PAT. 6 + PHA 4930 + 353 5.1 
PAT. 7 + PHA 807 + 241 0.8 
PAT. 8 + PHA 1147 + 448 1. 2 
NORMAL 1 + PHA 1097 + 256 1.1 
NORMAL 2 + PHA 1280 + 375 1. 3 
NORMAL 3 + PHA 1098 + 198 1.1 
Results are expressed as mean cpm + SD [3H]thymidine 
incorporation. Data represent the means of triplicate 
determinations. Stimulation indeces were calculated as 
follows: mean cpm in wells stimulated by test supernatant 
and PHA/mean cpm in wells containing medium and PHA. A 




Fig. 2.5. Effect of adding adherent cell supernatants 
obtained from patients with spontaneous proliferation to 
unseparated (US) and purified T (T) cells obtained from a 
known normal PPD responder. Adherent cell supernatants from 
two patients (SUP.1 and 2) were added to 1 x 105 unseparated 
control PBMC and cultured for 6 days. The same supernatants 
were added to 1 x 105 purified T cells in a parallel 
culture. The purified T cells were depleted of antigen 
presenting cells by twice rosetting with SRBC and adhering 
to plastic for 90 minutes. Proliferation was assessed by 
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proliferation did not stimulate either unseparated or 
purified T cells (Table 2.9). 
2.5. DISCUSSION AND CONCLUSIONS 




of persisting spontaneous 
blood lymphocytes in 
tuberculosis. The proliferation was dependent on the major T 
cell lymphokine IL-2 as evidenced by the presence of IL-2 
receptors on the proliferating cells and the ability to 
block with anti-IL-2-receptor antibody. The phenomenon was 
unlikely to be an ef feet of anti-tuberculous drugs since 
four of these patients received no therapy prior to 
inclusion in the study. In one case the proliferation 
persisted long after therapy was stopped. The data in Table 
1 indicates that a serum factor is unlikely since no change 
in the proliferation was observed when either autologous or 
pooled serum was used. The concentration of the serum also 
did not af feet the proliferation ( Table 2. 1) . The 
proliferation was also unlikely to be dependent on accessory 
cell derived prostaglandins since indomethacin had no effect 
on the proliferation (Table 2.2). 
Several levels of evidence implicate a role for persisting 
mycobacterial components in the initiation of this 
phenomenon. Firstly, the kinetics of the proliferation 
mirrored that of antigen driven proliferation (Table 2. 5). 
Secondly, the proliferation had a strict requirement for APC 
since ( i) adherent cell depletion abrogated the 
proliferation (Table 2.6) and (ii) adherent cell 
supernatants obtained from patients with high spontaneous 
proliferation caused significant proliferation only upon 
addition to unseparated control cells (Fig. 2. 5). The same 
supernatants did not stimulate highly purified T cells from 
the same control individual, suggesting a requirement for 
antigen presentation (Fig.2.5). Thirdly, adherent cell 
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Table 2. 9. Effect of adherent cell supernatants obtained 
from patients without spontaneous proliferation on 




MEAN CPM [3H]THYMIDINE INCORPORATION: 
UNSEPARATED CELLS PURIFIED T CELLS 
---------------------------------------------------------
MEDIUM 1397 + 386 819 + 61 
1 1911 + 283 1013 + 154 
2 1630 + 239 1420 + 110 
3 2435 + 682 1750 + 242 
Adherent cell supernatants were added to unseparated and 
purified T cells obtained from a known PPD responder and 
proliferation was assessed by [3H]thymidine incorporation on 




supernatants obtained from TB patients without spontaneous 
proliferation were inactive when added to unseparated 
control cells, despite similar levels of thymocyte co-
stimulatory activity to supernatants obtained from patients 
with spontaneous proliferation (Tables 2.8.1 and 2.8.2). It 
is well known that the thymocyte co-mitogenesis assay 
detects several lymphokines including interleukins 1 and 6. 
The data therefore indicates that the spontaneous 
proliferation was unlikely to be due to the direct effect of 
the cytokines alone. The most direct explanation for these 
data is the presence of antigen in the supernatant. Indeed, 
a recent in-vitro study confirmed the presence of processed 
antigenic determinants in supernatants of monocytes 
stimulated with optimal concentrations of mycobacterial 
antigen (127). Finally, the presence of antigen would also 
account for the observation that active adherent cell 
supernatants only caused proliferation when added to NAC 
obtained from patients with high spontaneous proliferation 
( Table 2. 7. 1) , and not when added to control NAC ( Table 
2.7.2). It is likely that the non-rigorous separation 
techniques employed in this study left residual accessory 
cells within the NAC population. These accessory cells may 
be capable of efficiently presenting antigen in spite of 
their low numbers. It is interesting to note that augmented 
antigen presentation is a feature of sarcoidosis (109), 
another granulomatous disorder associated with increased 
spontaneous proliferation (105,106). An alternative 
explanation is that the peripheral blood T lymphocytes in 
these patients have been primed to mycobacterial antigen in 
vivo, despite the inability to detect the classical 
activation markers HLA-DR and TAC. Primed T cells, unlike 
naive cells, can be triggered to proliferate in the absence 
of antigen presenting cells (128,129). Furthermore, even 
cloned T lymphocytes do not show a direct correlation 
between signal requirements for proliferation and HLA-DR or 
TAC expression (129,130). 
Persuasive experimental evidence indicates that even readily 
degradable protein antigens can indeed persist for months or 
years in the spleens and draining lymph nodes of immunized 
animals (100). Persisting antigen at these sites are thought 
to play a role in the maintenance and regulation of humeral 
immunity (101). Persisting antigen has also been implicated 
as a potential aetiological agent in a number of chronic 
diseases such as rheumatoid arthritis and chronic reactive 
arthritis following infection with Borrelia or Yersinia 
(102-104,110). 
Spontaneous proliferation is also a feature of rheumatoid 
arthritis (110). Significant differences exist in the 
spontaneous proliferation noted in both rheumatoid arthritis 
and sarcoidosis when compared to the findings in this study. 
Firstly, in both rheumatoid arthritis and sarcoidosis the 
proliferation is noted at the site of pathology ( synovial 
fluid (SF) and broncho-alveolar lavage (BAL) fluid 
respectively) as opposed to peripheral blood in the TB 
patients discussed herein. Secondly, the proliferation is 
apparently independent of antigen presenting cells and is 
present in highly purified T cells in both diseases 
(105,106,110). Thirdly, fresh lymphocytes obtained from the 
SF and BAL were found to express increased levels of 
activation markers such as HLA DR and TAC (109,110). These 
differences may be the result of in-vivo antigen 
presentation since interaction between T lymphocytes and 
antigen presenting cells is more likely at the site of the 
pathology than in the circulating peripheral blood. In the 
case of the TB patients, it is likely that in-vitro culture 
provides the appropriate environment for interaction between 
T cells and antigen presenting cells. This would result in 
the proliferation noted during in-vitro culture and account 
for the absence of activation markers on freshly isolated 
cells. It is likely that the spontaneous proliferation 
observed in-vitro in TB peripheral blood occurs in-vivo at 
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the site of pathology. In fact, spontaneous proliferation 
has been noted in unstimulated lymphocytes obtained from 
some pleural effusions (Table 6.1). 
Spontaneous proliferation has also been noted in hybridomas 
obtained from neonatal thymocytes ( 90). These hybridomas 
have been shown to express the gamma-delta T cell receptor 
and to react to the 65 kDa HSP (90). A considerable 
percentage of cells bearing this receptor, in the peripheral 
blood, respond to mycobacterial antigen. The antigen 
responsible for the spontaneous proliferation noted in the 
TB PBL may therefore be mycobacterial 65 kDa HSP or the 
human homologue. 
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The case represented by Fig.2.2.3 was particularly 
interesting. This patient had documented pulmonary TB four 
years previously which was fully treated. At the time of 
study, only non-specific symptoms of malaise and loss of 
weight were present. Persistent spontaneous proliferation 
was demonstrated over a 14 month period in the peripheral 
blood. Adherent cell supernatants from this patient was able 
to stimulate proliferation in control cells only in the 
presence of APC and, in addition, was able to sensitize 
targets for lysis by PPD-specific CTL (Sup.2 in Fig.2.5 and 
2.6). These observations strongly implicate the presence of 
mycobacterial antigen in this adherent cell supernatant. 
Although subclinical reactivation is possible, it cannot be 
excluded that the proliferation in this case may reflect an 
ongoing immune response dating to the original infection 
four years previously. The patient represented in figure 
2. 2. 1 was similar in that proliferation persisted for at 
least four months after all clinical and radiological 
evidence of disease had disappeared. 
Five of the six patients with spontaneous proliferation had 
extensive disease. Three had disseminated disease, one had 
extensive pulmonary disease with resistant organisms and the 
fifth case had suspected miliary TB. Three of these patients 
demonstrated poor response to therapy and were unwell for 12 
months or longer. The slow clinical resolution observed 
together with the demonstration that antigen persisted in 
these patients suggests that these patients have defective 
immunity. It is likely that phagocytes in these patients 
have poor microbicidal activity. In addition, it is also 
possible that these patients have decreased CTL activity. 
Unfortunately, due to technical considerations and limited 
access to these patients, these possibilities could not be 
pursued. 
The possibility that antigen was persistently secreted by 
circulating adherent cells is intriguing since these cells 
have a short lifespan in the peripheral blood (131). It is 
possible that a long-lived peripheral pool of adherent cells 
exist. A similar hypothesis was invoked to explain the long 
term effects of IFN-~ adminstration on circulating 
phagocytes in patients with chronic granulomatous disease 
(132). An alternative possibility is that mycobacterial 
antigen was being continuously seeded out into the 
circulation from infected tissue sites. Thus competent cells 
entering the circulation would be exposed to mycobacterial 
antigen. It is also possible that the bone marrow in these 
patients was infected. Mature cells already carrying 
mycobacterial antigen would then be released into the 
circulation . 
In conclusion, this is the first description of persistent, 
IL-2 dependent, spontaneous T lymphocyte prolif era ti on in 
tuberculosis. Previous immune abnormalities, namely 
necrotizing skin test responsiveness, abnormalities of 
glycosylation of the Fe portion of IgG, and increased 
1,25(0H)2D3 production have been shown to persist in 
patients with TB. The underlying mechanism for these 
61 
inexplicable immune phenomena is not known. The data 
described here represents a fourth persisting immune 
abnormality, and provides evidence that it may be due to 
persistent antigen secretion by adherent cells. Similar 
observations in rheumatoid arthritis and sarcoidosis suggest 
that these diseases may also represent ongoing inflammatory 
and immune responses to persisting antigen. Finally, our 
observations provide additional support for the concept that 
mycobacteria persist in the host in some form and are never 
totally eliminated (134). 
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CHAPTER 3 
CYTOTOXICITY BY PPD-STIMULATED LYMPHOCYTES: A COMPARISON OF 
THE CONVENTIONAL 4-HOUR SlcHROMIUM RELEASE ASSAY WITH THE 
EXTENDED 15-HOUR CHROMIUM RELEASE ASSAY 
3.1. ABSTRACT 
M. tuberculosis is a bacterial pathogen capable of survival 
and replication within human macrophages. CTL are thought to 
be important for the eradication of infected macrophages. To 
test this hypothesis, two assays were analyzed for the 
purpose of measuring in-vitro PPD-specific cytotoxicity. PBL 
from control PPD-responsive subjects were stimulated in-
vitro with PPD, and assayed for their cytotoxic capacity in 
conventional 4-hour Slchromium release assays. Autologous 
phytohaemagglutinin stimulated blasts maintained in IL-2 
were used as targets. No significant PPD-specific lysis 
could be demonstrated using this system. Significant lysis 
could however be demonstrated by using a 15-hour chromium 
release assay which utilized autologous adherent cells as 
targets. 
3.2. INTRODUCTION 
The hypothesis that CTL are important for protection against 
mycobacteria is an attractive one. It is known that 
mycobacteria may persist within parasitized macrophages 
(12). IFN-~ activated macrophages have not been convincingly 
shown to inhibit growth of M. tuberculosis in humans ( 30-
37). Lysis of parasitized macrophages by specific CTL would 
destroy the organisms environment and expose them to more 
hostile macrophages as well as alternative immune mechanisms 
(12). A failure in such a mechanism could then conceivably 
result in persistence of the infection and ongoing immune 
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activation as described in chapter 2. As a result of 
technical difficulties (particularly ill patients who could 
not be repeatedly venesected for the provision of target 
cells) this hypothesis could not be pursued further in the 
patients with spontaneous proliferation. As an alternative, 










To date, significant PPD-specific cytotoxicity has been 
demonstrated in only one human study when the conventional 
4-hour chromium release assay was used ( 43). Most other 
studies have used a 15-hour chromium release assay which 
employs adherent cell targets obtained from the peripheral 
blood (46-48). Here, the two methods are compared to 
standardise an assay system for the measurement of PPD-
specif ic cytotoxicity. 
3.3. MATERIALS AND METHODS 
3.3.1. Cell separation and preparation of effectors 
PBMC were obtained from control PPD responders by Ficoll-
Hypaque density gradient centrifugation as described in 
chapter 2. 3. 3. The PBMC were stimulated with 3µg/ml PPD 
(Connaught Laboratories, Willowdale, Ontario, Canada) for 6 
days. 
3.3.2. 4-hour chromium release assay 
Targets were autologous Phytohaemagglutinin ( PHA, H A 16, 
Welcome Diagnostics, Temple Hill, Dartford, England) 
stimulated blasts maintained in IL-2. Targets ( 2-4 x 106) 
were labelled with 250 µCi Slsodium chromate (specific 
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activity 3.7-13Gq/mg, Amersham International, Amersham, 
U.K.) at 370c for 1 hour in 0.1 ml of medium. The targets 
were washed 3 times in PBS and labelled with varying 
concentrations of PPD (ranging from lOµg to SOµg/ml) for 3 
hours on the day of the assay or overnight prior to the 
assay. Some target cells were labelled with PPD both 
overnight prior to the assay and for 1 hour on the day of 
assay. Control target cells were not labelled with antigen 
or were labelled with streptokinase-streptodornase (SK-SD, 
1: 100 dilution, Leder le Lab., Wayne, N. J., U.S.A. ) . The 
assay was performed in triplicate in U-bottomed microtitre 
plates (Flow Laboratories) in complete medium. Labelled 
target cells were plated at 3 x 103 per well and effectors 
were added to target cells at varying E/T ratios in a final 
volume of 0.2 ml per well. Some wells contained target cells 
and complete medium without effectors for the determination 
of spontaneous release. Triton-X (5%, BDH 30632, BDH LTD, 
Poole, England) was added to some wells for the 
determination of maximum chromium release. Plates were spun 
at 150G for 5 minutes and incubated at 370c for 4 hours 
after which 130 µl of the supernatant from each well was 
removed into disposable counting tubes (Greiner, Nurtingen, 
West Germany) and counted in a gamma counter (Packard, auto-
gamma scintillation spectrometer). The percentage specific 
release was calculated by: 100 x [(mean cpm experimental) -
(mean cpm spontaneous release)]/[(mean cpm maximum release) 
- (mean cpm spontaneous release)]. 
3.3.3. 15-hour chromium release assay 
The cytotoxic 
stimulated for 
capacity of effector cells 
4 or 6 days with PPD in 
which had been 
24 well tissue 
culture plates (Nunc, Kamstrup, Denmark) was assayed as 
previously described (47). Target cells were day 4 or day 6 
autologous adherent cells of PBMC that had been plated in 
96-well U-bottomed tissue culture plates (Nunc, Kamstrup, 
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Denmark). Approximately 10% adhered. This number was used 
for calculating E/T ratios. One day prior to assay the 
targets were pulsed with antigen (PPD lOµg/ml or SK-SD 1:100 
dilution) and labeled with 6 µCi of Slsodium chromate 
(specific activity 3.7-13Gq/mg, Amersham International, 
Amersham, UK) during 18 hours culture at 37 °c and then 
washed three times with preheated (37 °c) medium. Effector 
cells ( 100 µl/well) were then added in triplicate to the 
target cells at E/T ratios of 10, 3 and 0.3. Wells 
containing medium only were used for the determination of 
spontaneous release. The assays were then incubated at 37°c 
in a humidified atmosphere containing 5% CO2, 15 hours later 
the total supernatant content of each well was transferred 
to a disposable counting tube (Greiner, Nurtingen, West 
Germany) and 100µ1 of triton-X was added to the remaining 
adherent cells for the determination of maximum release. 
After 3 hours the total volume of triton-X was transferred 
to similar tubes and the samples were counted in a gamma 
counter (Packard, auto-gamma scintillation spectrometer). 
The percentage-specific killing for the mean of triplicate 
wells was calculated as follows: percent specific lysis = 
[mean test cpm/ (mean test cpm + mean cpm after triton-X 
treatment of the same triplicate wells)] x 100% - percent 
spontaneous release. The percentage spontaneous release was 
calculated as follows: mean cpm in spontaneous release 
wells/ (mean cpm in spontaneous release wells + mean cpm 
after tri ton-X treatment of the same triplicate wells) x 
100%. Cytotoxicty was considered significant if greater than 
5% (133). 
3.4. RESULTS 
3.4.1. Technical data 
In the 15-hour assay, the mean percentage spontaneous 
release (+ SD) of chromium by all targets was 18 + 5 (n = 
9 2) . The mean percentage spontaneous release ( + SD) from 
targets treated with PPD and SK-SD was 19 + 5 (n = 22) and 
18 + 5 (n = 22) respectively. The mean percentage 
spontaneous release (+ SD) by untreated targets was 20 + 6 
( n = 22) Similar results were obtained in the 4-hour 
assay. 
3.4.2. Failure to demonstrate significant cytotoxicity with 
the conventional 4-hour chromium release assay 
No significant lysis was obtained in the majority of 
experiments when the conventional 4-hour chromium release 
assay was used (Tables 3.1.1, 3.1.2 and 3.2). In the 
minority of experiments, low levels of cytotoxici ty were 
observed at 4 hours (Tables 3.1.1, 3.1.2, 3.2 and 3.3). No 
significant increase in lysis was observed even when PBL 
targets were pulsed with antigen for extended periods (Table 
3.2). Similarly no increase in lysis was observed when 
higher E/T ratios were used, or when higher doses of antigen 
were used to pulse targets (Tables 3.2 and 3.4). Significant 
antigen-specific lysis was observed when the 15-hour 
chromium release assay was used (Tables 3.1 and 3.3). 
3.4.3. Comparison of cytotoxicity at 4, 7 and 15 hours in 
the assay employing adherent cell targets 
Only low levels of cytotoxici ty were observed at 4 and 7 
hours. Significant cytotoxicity was observed at 15 hours 
(Table 3.3). 
3.4.4. Cytotoxicity against targets pulsed with varying 
doses of antigen in the 15-hour assay 
No significant difference in cytotoxicity was observed over 
the dose range employed for labelling of targets in the 15-
hour assay (Table 3.5). 
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Table 3.1.1. Mean PPD-specific cytotoxicity of ten control 
subjects as measured in the 15-hour chromium release assay 
compared to mean PPD-specific cytotoxicity in 16 experiments 
utilizing the 4-hour chromium release assay. 
Assay type E/T ratio 
15-hour 10 39 
3 31 
0.3 13 
4-hour 10 3 
3 2 
1 1 
% SPECIFIC LYSIS OF 
TARGETS PULSED WITH: 
PPD SK-SD+ NO Ag* 
+ 5 8 + 2 6 + 3 
+ 5 4 + 1 4 + 2 




Results are expressed as mean percentage specific lysis + SE 
of 10 and 16 experiments respectively. All the subjects used 




Table 3 . 1. 2 . Cytotoxici ty by PPD-stimulated effectors 
obtained from a single subject in a conventional 4-hour 
chromium release assay compared to a 15-hour chromium 
release assay. 








% SPECIFIC LYSIS OF 
TARGETS PULSED WITH: 
PPD SK-so+ NO Ag* 
7 0 3 
0 0 0 
0 0 0 
0 0 0 
36 2 0 
27 0 0 
8 0 0 
Results are expressed as the mean percentage specific lysis 
of triplicate cultures as described for each assay type in 
materials and methods. SD were mostly less than 10%. 
Effector and target cells for both assays were obtained at 
the same time from a single control subject. Effectors were 
stimulated for 6 days with 3 µg/ml PPD and targets were 




Table 3. 2. Ef feet of extended antigen pulsing of target 
cells, on cytotoxicity, in conventional 4-hour chromium 
release assays. 















% SPECIFIC LYSIS OF TARGETS 















































Results are expressed as the mean percentage specific lysis 
of triplicate cultures as described in materials and 
methods. SD were mostly less than 10%. 
*o/N, overnight 
#o/N + 1 hour, targets incubated with PPD overnight and 
treated again with PPD the following morning 
for one hour 
+ND, not done 
Table 3.3. PPD-specific cytotoxicity at 4, 7, and 15 hours 









% SPECIFIC LYSIS OF 













Results are expressed as the mean percentage specific lysis 
of triplicate cultures as described in materials and 
methods. SD were mostly less than 10%. 
All experiments were per£ armed at an effector to target 
ratio of 10: 1. 
*Ag, antigen 
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Table 3.4. PPD-specific cytotoxicity in the conventional 4-
hour chromium release assay against target cells pulsed with 








PERCENT SPECIFIC LYSIS 















Results are expressed as the mean percentage specific lysis 
of triplicate cultures as described in materials and 
methods. SD were mostly less than 10%. All experiments were 
performed at an effector to target ratio of 10:1. 
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Table 3.5. Effect of target cells pulsed with varying 
concentrations of PPD antigen, on cytotoxicity, in the 15-








PERCENT SPECIFIC LYSIS 
OF TARGETS PULSED WITH: 







Results are expressed as the mean percentage specific lysis 
of triplicate cultures as described in materials and 
methods. SD were mostly less than 10%. 
Effectors were PBL (obtained from a control subject) 
stimulated with Connaught PPD for 6 days. 
All experiments were performed at an effector to target 
ratio of 3:1. 
* Evans PPD (Evans corporation, England, United Kingdom) 
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3.5. DISCUSSION AND CONCLUSIONS 
The data indicates that only low levels of cytotoxicity were 
generated at 4 hours irrespective which assay system was 
employed. The failure to demonstrate cytotoxicity in the 4-
hour assay was clearly confirmed by the experiment 
illustrated in Table 3 .1. 2. In this experiment, a single 
culture of effector cells was appropriately divided between 
the two assay types and identical E/T ratios were used. The 
targets were also treated with the same amount of antigen. 
At an E/T ratio of ten, only 7% lysis was noted against 
autologous PBL targets treated with PPD in the 4-hour assay 
as compared to 36% lysis directed at autologous adherent 
cell targets treated with PPD in the 15-hour assay. 
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The low levels of lysis observed in the 4-hour assays were 
unlikely to be due to too brief an exposure of target cells 
to antigen since even extended periods of exposure to 
antigen at high concentrations made no difference to the 
levels of cytotoxici ty ( Tables 3. 2 and 3. 4) . Furthermore, 
minute amounts of antigen were adequate to sensitize targets 
for antigen-specific lysis in the 15-hour assay (Table 3.5). 
The cytotoxicity was mostly directed at targets treated with 
PPD and was highest at high E/T ratios. Low levels of 
cytotoxici ty was directed at untreated targets or targets 
treated with SK-SD. The non-specific kill was greater at the 
highest E/T ratios and was almost certainly NK or LAK 
mediated. This was confirmed later (Chapter 4). 
Both assay systems were found to be technically reliable and 
reproducible. Targets were successfully chromated in both 
assay systems. Poor chromation and poor viability (as 
assessed by trypan blue exclusion) precluded the use of 
resting PBL as targets as was done in a previous study (43). 
Spontaneous release of chromium was considered acceptable if 
less than 30% of maximum release after addition of Triton-X. 
This was much more stringent than was recommended ( 133). 
From the results it is clear that pre-incubation with 
antigen did not affect percentage spontaneous release. 
Preliminary experiments with the 15-hour assay demonstrated 
no significant differences in percentage spontaneous release 
when day 4, day 6 or fresh PBL adherent cells were employed 
as targets. Cytotoxici ty was also not significantly 
different. Thus day 4 or day 6 adherent cells were used in 
most experiments as this required a single venesection of 
the subject under study. 
The cytotoxicity observed at 15 hours, in the assay 
employing autologous adherent targets, is mediated by co4+ 
CTL (section 4.4.5). The mechanism of cytotoxicity utilized 
by C04 + CTL may possibly account for the delay observed 
before significant cytotoxicity was detected. 
Cytotoxicity observed at 4 hours in the conventional 
chromium release assay has in most cases been shown to be 
mediated by cos+ CTL (52,55). cos+ CTL recognize antigen in 
association with MHC class I products (52,55). Exogenously 
added antigen usually enters the class II pathway of antigen 
processing (52,55). This may therefore account for the 
failure to demonstrate cytotoxicity at 4 hours. This 
possibility is addressed in chapter 5. 
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CHAPTER 4 
CELL MEDIATED CYTOTOXICITY IN TUBERCULOSIS: A COMPARISON OF 
CYTOTOXICITY BY PLEURAL EFFUSION, AUTOLOGOUS PERIPHERAL 
BLOOD AND CONTROL PERIPHERAL BLOOD LYMPHOCYTES 
4.1. ABSTRACT 
Numerous theoretical considerations suggest that CTL are 
important in the immune response to M. tuberculosis. To 
pursue this hypothesis, the level and kinetics of generation 
of antigen-specific cytotoxicity of in-vitro PPD-stimulated 
PEL was determined using 15-hour Slchromium release assays. 
Cytotoxicity in PEL obtained from patients with tuberculous 
pleuri tis was compared with that in cells obtained from 
autologous peripheral blood, control peripheral blood and 
non-tuberculous effusions. In 6 tuberculous pleural 
effusions, both proliferation and cytotoxicity were 
augmented and accelerated in comparison to autologous or 
control peripheral blood. By contrast, low levels of 
cytotoxici ty with conventional kinetics of induction were 
observed in non-tuberculous effusions. Cell subset 
fractionation experiments indicated that the cytotoxici ty 
was mediated by co4+ cells. The accelerated kinetics of 
induction of PPD-specific CTL demonstrated here suggests 
reactivation of in-vivo generated CTL. These findings 
provide evidence that CTL are induced at the site of 
pathology in-vivo, and suggest that these cells have a role 
in in-vivo protection against infection with tuberculosis. 
4.2. INTRODUCTION 
A reliable and reproducible assay system for determining 
PPD-specific cytotoxicity was established in Chapter 3. In 
this section the objective was to apply this assay to assess 
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cell mediated cytotoxicity in patients with tuberculous 
pleuritis. 
Pleural effusions provide 
immune function in cells 
a unique opportunity to study 
obtained from the site of the 
pathology. The disease is common and the lymphocytes in the 
pleural fluid are usually numerous and easily accessible. 
Furthermore, the viability of these cells as determined by 
trypan blue exclusion is almost 100%. This contrasted with 
lymphocytes obtained from BAL fluid where only small numbers 
of lymphocytes were obtained and viability was low. 
Cellular immunity is thought to be effective in tuberculous 
pleural effusions because many are known to resolve 
spontaneously ( 135). This constituted another indication 
for analyzing T cell function in pleural effusions as this 
was the site most likely to yield evidence of in-vivo cell 
mediated cytotoxicity. Circumstantial evidence implicating 
an in-vivo role for cell mediated cytotoxicity has been 
described in Leprosy (46). Such evidence is not available in 
human tuberculosis. 
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Proliferation and cytotoxici ty was measured on days one, 
four and six since a significant earlier response would 
imply a secondary immune response and therefore in-vivo 
priming with mycobacterial antigen. The level of 
cytotoxicity by pleural effusion lymphocytes was also 
compared to that in autologous peripheral blood and control 
peripheral blood as it was argued that cytotoxicity would be 
augmented, in active disease at the site of the pathology, 
if it was involved in protective immune responses. 
The phenotypic nature of the cell responsible for antigen-
specific lysis in the 15-hour assay was established by 
utilizing cell separation techniques. These cells were shown 
to be MHC class II restricted. In addition, PEL NK activity 
was analyzed in 4-hour chromium release assays to 
characterize the nature of the antigen non-specific lysis 
noted in the 15-hour assays. 
4.3. MATERIALS AND METHODS 
4.3.1. Patient population 
Pleural fluid and peripheral blood samples were obtained at 
the time of closed pleural biopsy in 7 patients with newly 
diagnosed tuberculous pleural effusions, seen at Groote 
Schuur Hospital between July and December 1989. Pleural 
biopsy revealed granulomatous pleuritis in 5 cases (with the 
presence of M.tuberculosis in 1). Tuberculosis was diagnosed 
in one patient with constrictive pericarditis and pleural 
effusion on the basis of the clinical picture and response 
to therapy. In the remaining case M.tuberculosis was 
cultured from the sputum. Pleural fluid was also obtained 
from 5 patients with non-tuberculous aetiologies 
(malignancy, 3 cases; parapneumonic effusion, 1 case; non-
specific inflammation, 1 case). Peripheral blood samples 
were also obtained from 10 PPD-responsive control subjects 
for the analysis of cytotoxicity. 
4.3.2. Proliferation assay 
78 
Peripheral blood lymphocytes (PBL) and pleural effusion 
lymphocytes (PEL) were separated on a Ficoll-Hypaque 
gradient as described in chapter 2, the only modification 
being that pleural effusions were overlaid directly onto 
Ficoll-Hypaque without diluting first. PBL or PEL (1 x 105) 
were resuspended in complete medium and added to wells of 96 
well round bottomed sterile tissue culture plates (Flow 
Laboratories). Cells were stimulated with 3 µg/ml PPD 
(Connaught Laboratories, Willowdale, Ontario, Canada) except 
for some wells which contained responder cells alone for the 
determination of background proliferation. Cultures were 
incubated at 37 oc in a humidified atmosphere containing 5% 
CO2 and pulsed with Tritiated thymidine (2 µCi/well, 
specific activity 185 Mega BQ, Amersham 120, Amersham, U.K.) 
on day 1, 3 or 6 for the final 16-18 hours of incubation. 
The cells were harvested using an automated harvester 
(Titertek 630), and radioactivity was measured using a 
liquid scintillation counter (Packard, Tricarb 4640). All 
assays were performed in triplicate. Results were expressed 
as lymphocyte transformation indexes (LT!) . The LT! was 
calculated as follows: LT! = mean counts per minute in 
antigen stimulated wells/mean counts per minute in 
unstimulated wells. 
4.3.3. Cytotoxicity assays 
The percentage specific chromium release was determined 
after 4 or 15 hours of incubation. Effector cells ( 1 x 
106/well) were stimulated with 3 µg/ml PPD and cultured for 
1, 4 or 6 days and utilized in the relevant assays. 
4.3.3.1. The 4-hour assay. 
Natural killer (NK) activity was evaluated in a standard 4-
hour chromium release assay as described in 3.3.2., with the 
exception that: (1) the E/T cell ratio was 30:1, 10:1, 3:1, 
and 1:1.; and (2) the K562 cell line served as target cells. 
4.3.3.2. The 15-hour assay. 
The 15-hour chromium release assay was performed as 
described in section 3. 3. 3. , with the exception that the 
assay was also performed using targets and effectors 
obtained on day 1 of culture. For the results shown in Table 
4.5, cytotoxicity was expressed in the number of lytic units 
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(LU) for each effector cell population, calculated from the 
linear portion of the dose response curve: 1 LU was defined 
as the number of effector cells required to cause 25% lysis 
from 1 x 104 adherent monocytes (15-hour assay) or 3 x 103 
K562 target cells (4-hour assay) (136), 
4.3.4. Isolation of T cell subsets 
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Enriched lymphocyte subsets were obtained by a panning 
technique as previously described (137). Unfractionated day 
5 PPD-stimulated lymphocytes (1 x 107) were incubated with 
Leu 16 ( Becton Dickinson, Mountain View, U.S.A.) for 45 
minutes at 40c. The cells were subsequently washed twice in 
3%HS-PBS and incubated for 1 hour in petri dishes that were 
previously coated with affinity purified goat anti-mouse IgG 
(Tago, Burlingame, California, U.S.A.) at 100 µg/10 ml/petri 
dish in Tris buffer, pH 9. 5. B cells and monocytes ( by 
plastic adherence) were thus removed during this stage. 
After this preliminary incubation, the cells were washed and 
incubated with TB ascites (ATCC). After 45 minutes, the 
cells were washed twice in 3% HS-PBS and incubated in a 3 ml 
volume in goat anti-mouse IgG coated petri dishes as above. 
After 2 hours NAC (CD4+ enriched) were collected. Following 
4 gentle washes to remove remaining NAC, the adherent cells 
(CD8+ enriched) were removed by vigorous pippeting. The 
cells were incubated overnight at 370c in complete medium 
and utilized in cytotoxicity assays the following day. 
4.3.5. Immunostaining 
T4 or T8 ascites (50 µl, ATCC) was added to 106 mononuclear 
cells suspended in 100 µl of fluorescence mixture (3% FCS-1% 
Na-azide-PBS). Primary antibody was ommitted from cells 
serving as a background control for fluorescence. After 
incubation at 4 °c for 40 minutes, the cells were washed 3 
times with fluorescence mixture. A FITC-conjugated goat 
anti-mouse IgG was added as a secondary antibody. Cells were 
washed after 30 minutes and percentage positive cells 
analyzed by indirect fluorescence microscopy when at least 
200 cells were counted. 
4.3.6. Statistical analysis 
Confidence intervals were calculated as described (126). 
Analysis of variance by comparison of means was used to 
calculate P values. 
4.4. RESULTS 
4.4.1. Comparison of cytotoxicity on day 4 and day 6 by PEL 
and autologous PEL 
In PBL, generally low levels of cytotoxicity were detectable 
on day 4, and a wide range of cytotoxicity was observed on 
day 6, (Table 4.1). These kinetics were paralleled by 
proliferation data which were available for 4 of 6 patients 
(Table 4.1). 
By contrast, the striking finding with PEL was accelerated 
kinetics with respect to both cytotoxicity and proliferation 
(Table 4.2). All 6 patients had high levels of cytotoxicity 
directed at PPD labelled targets, already detectable by day 
4 of culture. Cytotoxicity was markedly reduced by day 6 in 
2 of the 6 patients and remained on a plateau in the 
remaining 4 patients. Similarly, proliferative responses to 
PPD peaked on day 4, al though day 6 LTI were markedly 
elevated compared to PBL. 
4.4.2. Level of cytotoxicity by PEL compared to PEL 
The mean peak PPD-specific cytotoxicity by PEL of 6 patients 
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Table 4 .1. Cytotoxicity of PPD-stimulated PBL obtained from 
patients with tuberculous pleuritis. 
PERCENT SPECIFIC LYSIS 
OF MONOCYTES PULSED WITH: 
-------------------------Patient Day LTI* E/T ratio PPD SK-sD+ NO Ag# 
------------------------------------------------------------
1 4 2 10 9 0 0 
3 0 0 0 
0.3 0 0 0 
6 3 10 39 17 13 
3 12 6 0 
0.3 1 0 2 
2 4 5 10 5 6 0 
3 0 0 0 
0.3 0 0 0 
6 16 10 16 7 9 
3 8 4 6 
0.3 0 0 0 
3 4 6 ND** 
6 22 10 7 0 0 
3 3 0 0 
0.3 0 0 0 
4 4 14 10 36 18 21 
3 17 0 6 
0.3 10 0 1 
6 66 10 50 31 18 
3 41 15 7 
0.3 15 4 1 
5 4 ND 10 20 2 6 
3 9 0 0 
0.3 1 0 0 
6 ND 10 48 0 6 
3 27 0 4 
0.3 7 0 0 
6 4 ND 10 16 0 0 
3 6 0 0 
0.3 0 0 0 
6 ND 10 25 5 6 
3 16 3 3 
0.3 9 5 5 
FOOTNOTES TO TABLE 4.1. 
Results are expressed as the mean percentage specific lysis 
of triplicate cultures calculated as described in Materials 
and Methods. SD were mostly less than 10%. 
*LTI, lymphocyte transformation index 
+sK-SD, streptokinase-streptodornase 
#Ag, antigen 
**ND, not done 
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Table 4.2. PPD-stimulated cytotoxicity by tuberculous PEL. 
PERCENT SPECIFIC LYSIS 
OF MONOCYTES PULSED WITH: 
Patient Day LTI* E/T ratio PPD SK-so+ NO Ag# 
------------------------------------------------------------
1 4 87 10 56 35 34 
3 51 21 25 
0.3 38 14 15 
6 32 10 70 6 7 
3 65 2 0 
0.3 33 0 0 
2 4 83 10 66 39 42 
3 45 19 26 
0.3 17 3 2 
6 51 10 62 28 24 
3 42 13 9 
0.3 8 0 0 
3 4 52 10 46 4 2 
3 24 0 1 
0.3 5 0 0 
6 27 10 22 1 1 
3 11 0 1 
0.3 1 0 0 
4 4 94 10 50 22 22 
3 38 2 5 
0.3 15 0 0 
6 73 10 60 20 13 
3 49 8 1 
0.3 25 1 2 
5 4 ND** 10 56 11 8 
3 32 0 0 
0.3 1 0 0 
6 ND 10 11 0 0 
3 0 0 0 
0.3 0 0 0 
6 4 ND 10 62 13 19 
3 46 3 0 
0.3 27 0 0 
6 ND 10 60 24 28 
3 35 7 8 
0.3 10 1 1 
FOOTNOTES TO TABLE 4.2. 
Results are expressed as the mean percentage specific lysis 
of triplicate cultures calculated as described in Materials 
and Methods. SD were mostly less than 10%. 
*LTI, lymphocyte transformation index 
+sK-SD, streptokinase-streptodornase 
#Ag, antigen 
**No, not done 
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with TB was significantly higher than that observed by 
autologous PBL (Fig. 4.1). At an E/T of 10:1, the difference 
between the mean peak cytotoxicity in PEL and autologous PBL 
was 26, with a 95% confidence interval from 8.6 to 43.4; The 
t test statistic was 2.2, with 10 degrees of freedom and an 
associated P value of P < 0. 01. At an E/T of 3: 1, Mean 
difference 26, 95% CI 7.1 to 44.9; t = 2. 2, df = 10, p < 
0. 01. At an E/T of 0.3:1, Mean difference 14, 95% CI 1.1 to 
26.9; t = 2.2, df = 10, p > 0.05. Thus statistical 
significance was not achieved only at the lowest E/T ratio. 
The mean peak PPD-specific cytotoxicity in PEL of six 
patients with TB was also significantly higher than that 
measured in ten control PPD responders (Fig. 4.2). At an E/T 
of 10:1, Mean difference 20, 95% CI 11.6 to 28.4; t = 2.2, 
df = 14, P < 0.01. At an E/T of 3:1, Mean difference 16, 95% 
CI 5.7 to 26.3; t = 2.2, df = 14, P < 0.01. At an E/T of 
0.3:1, Mean difference 8, 95% CI -2.9 to 18.9; t = 2.2, df = 
14, P > 0.05. Thus, statistical significance was again not 
achieved only at the lowest E/T ratio. 
4.4.3. Cytotoxicity in non-tuberculous effusions 
In effectors obtained from non-tuberculous effusions, 
generally low levels of antigen-specific cytotoxicity were 
observed on day 4 (Table 4. 3). In patient 1, significant 
cytotoxicty was observed on day 4 against all three targets. 
However, cytotoxicity of PPD-labelled targets was not 
enhanced in spite of a high LT! of 72, in marked contrast to 
what was seen in TB effusions. In two patients significant 
PPD-specific cytotoxicity was observed on day 6. 
4.4.4. Results of panning 
Fluorescence microscopy confirmed negatively selected cells 
to be 81% and 78% CD4 positive in two experiments. 
Negatively selected cells were CD8 negative in both 
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Fig. 4.1. Mean peak PPD-specific cytotoxicity by PEL of 6 
patients with TB compared to autologous PBL. Cytotoxicity is 
expressed as mean+ standard error and is markedly elevated 
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Fig. 4.2. Mean peak PPD-specific cytotoxicity by PEL of 6 
patients with TB compared to PBL obtained from 10 control 
PPD responders. Cytotoxicity is expressed as mean+ standard 
error and is significantly greater in the PEL. 
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Table 4 . 3 . PPD-stimulated cytotoxicity by non-tuberculous 
PEL. 
PERCENT SPECIFIC LYSIS 
OF MONOCYTES PULSED WITH: 
-------------------------
E/T NO 
Patient Day LTI* ratio PPD SK-so+ ANTIGEN 
------------------------------------------------------------
1 4 72 10 28 34 34 
3 22 21 13 
0.3 7 15 3 
6 77 10 54 13 6 
3 40 5 1 
0.3 14 4 1 
2 4 11 ND# 
6 39 10 29 15 8 
3 25 0 0 
0.3 12 0 2 
3 4 5 10 4 ND ND 
6 7 10 8 8 2 
3 0 5 2 
0.3 0 0 0 
4 4 ND 10 5 ND 0 
3 4 ND 0 
0.3 1 ND 0 
6 ND 10 4 0 0 
3 2 0 0 
0.3 1 0 0 
5 4 2 10 0 0 0 
3 0 0 0 
0.3 0 0 0 
6 1 10 0 0 0 
3 0 0 0 
0.3 0 0 0 
FOOTNOTE TO TABLE 4.3. 
Results are expressed as the mean percentage specific lysis 
of triplicate cultures calculated as described in Materials 
and Methods. SD were mostly less than 10%. 
*LTI, lymphocyte transformation index 
+sK-SD, streptokinase-streptodornase 
#No, not done 
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experiments. Positively selected cells were 56% and 48% CD8 
positive respectively. Positively selected cells were CD4 
negative in both experiments. 
4.4.5. Cytotoxicity by PEL is mediated by CD4+ cells 
The cytotoxicity observed in the CD4+ enriched population, 
negatively selected by panning, was enhanced in comparison 
to both the unseparated control cells, as well as the 
positively selected ens+ subset (Fig. 4.3 and Table 4.4). 
4.4.6. Kinetics and specificity of PPD-induced cytotoxicity 
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In the experiments shown in Tables 4.1-4.3, significant 
cytotoxicity with little or no antigen non-specific kill was 
frequently observed at the lowest E/T ratio tested (0.3:1). 
At higher E/T ratios, lysis of SK-SD-pulsed and unpulsed 
target cells was observed, and this probably represented 
natural killer ( NK) or lymphokine activated killer ( LAK) 
activity ( 46). Therefore, the kinetics and specificity of 
cytotoxic T cell generation, following PPD stimulation, was 
further evaluated by the simultaneous measurement of NK-
activi ty ( 4-hour chromium release assay using K562 target 
cells) and CD4+-mediated cytotoxicity (15-hour chromium 
release assay) on days 1, 4, and 6 of culture. 
Representative results from a patient with proven 
tuberculous pleuri tis are shown in Table 4. 5. In order to 
concisely display a large amount of relevant data, results 
were expressed in lytic units (as defined in Materials and 
Methods). This provided an overall quantitative expression 
of the data for the entire dose-response curve for each 
effector population, and was thus the best quantitative 
comparison of cytotoxicity. Comparison of % cytotoxicity 
values at one E/T cell ratio could have been misleading. The 
following conclusions can be drawn from the data : (i) low 
Fig. 4.3. Comparison of cytotoxicity in CD4 and CD8 enriched 
subsets of PEL obtained from a patient with TB. PPD-specific 
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PERCENT SPECIFIC LYSIS 
















Lymphocytes were enriched for the CD4 subset by a panning 
technique and assayed for cytotoxic capacity in a 15-hour 
51chromium release assay. 
Results are expressed as the mean percentage specific lysis 
of triplicate cultures calculated as described in Materials 
and Methods. SD were mostly less than 10%. 
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Table 4.5. Specificity and kinetics of PPD-stimulated 
cytotoxic activity. 
NATURE OF TARGET CELLS/ANTIGEN 
--------------------------------------------
AUTO LOGO US ALLOGENEIC 
MONOCYTES MONOCYTES 
----------------- -----------------
Day Effector K562 No Ag PPD SK-SD No Ag PPD SK-SD 
----------------------------------------------------------
1 PBL 10 2 4 2 2 2 2 
PEL 16 2 6 4 2 3 <2 
4 PBL 304 3 22 4 <2 8 <2 
PEL 73 5 61 6 2 29 <2 
6 PBL 69 5 31 4 ND ND ND 
PEL 26 <2 31 <2 ND ND ND 
Comparison of cytotoxicity by PPD-stimulated effectors are 
shown after 1, 4, and 6 days of culture. NK activity was 
measured in a 4-hour chromium release assay. Results are 
expressed as lytic units/106 effector cells as stated in 
Methods. The tissue typing of the donor of the effector 
cells was A26,w33,Bl4,w42,DRwl8,wl4,DQwl,w4 and that of the 




antigen-specific cytotoxicity was already present on day 1 
of culture. (ii) In the pleural fluid an accelerated pattern 
of PPD-specific cytotoxicity was observed, peaking on day 4 
of culture, as was seen in the 6 patients shown in Table 
4.2. (iii) Despite the presence of significant NK-like 
activity against K562 target cells on day 4 and 6 of 
culture, the cytotoxicity which was observed in the 15-hour 
assay was both antigen-specific and HLA class 11 restricted. 
Significant kill was observed only on PPD-pulsed autologous 
and heterologous target cells sharing HLA-DQwl with the 
donor, but not the heterologous target cells which were 
pulsed with the irrelevant antigen SK-SD, or no antigen. 
Additional evidence that the antigen non-specific kill was 
mediated by CD4 and CDS negative NK or LAK cells was 
obtained from cytotoxicity assays employing enriched 
effector cell populations. Antigen non-specific kill was 
almost totally abrogated in the CD4 enriched effector cell 
population ( Table 4. 4) . This contrasted strongly with the 
high levels of antigen specific kill seen in these assays 
(Fig. 4.3 and Table 4.4). 
4.5. DISCUSSION AND CONCLUSIONS 
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These results indicate that antigen-specific cytotoxicity in 
PEL is significantly enhanced when compared to autologous 
and control PBL. In addition, accelerated kinetics of 
induction were observed with high levels of cytotoxici ty 
already present by day 4. These findings, taken together 
with the clinical observation that most tuberculous pleural 
effusions resolve spontaneously, strongly implicate an in-
vivo role for CTL in protection against mycobacteria. They 
also provided support for the current hypothesis that CTL 
are important in protection against mycobacterial infections 
(12). This hypothesis is attractive on two counts. Firstly, 
it would provide a mechanism for the destruction of 
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parasitized macrophages and secondly, the lysis of 
macrophages would prevent excessive suppression since it is 
known that macrophages are capable of suppressing the immune 
response in TB (41). 
It is known that pleural effusions are enriched for PPD 
responsive CD4+ cells, particularly those of the memory 
phenotype ( 138-141). These probably represent a 
heterogeneous population of cells, containing both helper 
and cytotoxic subsets. In the presence of active infection, 
these cells are likely to be in-vivo activated. Indeed, 
spontaneous proliferation in lymphocytes obtained from 
several patients with tuberculous pleuritis has been 
documented (chapter 7). The high peak levels of cytotoxicity 
obtained upon in-vitro stimulation of PEL with PPD, together 
with the accelerated kinetics of induction seen, strongly 
resembles secondary CTL responses obtained in immunized mice 
( 142). This indicates that PPD-specific CTL have already 
been generated in-vivo, and it is likely, therefore, that 
the CD4 + memory PEL are also enriched for precursor CTL. 
Available markers cannot differentiate helper from CTL 
within the CD4+ subset, and limiting dilution analysis would 
be required to measure precursor frequencies of PPD-specific 
CTL in PEL (143). 
The data also clearly demonstrates a dissociation between 
proliferative and cytotoxic responses. No significant 
antigen-specific cytotoxicity was generated on day 4 by 
patient 1 in Table 3 in spite of a vigorous proliferative 
response (LTI=72). This is likely to be due to a relatively 
low frequency of antigen-specific precursor cytotoxic cells 
in this non-tuberculous effusion, since significant 
cytotoxici ty was present by day 6 of culture. Similarly, 
preliminary observations in this laboratory indicate that 
only low levels of PPD-specific cytotoxicity are generated 
by synovial T lymphocytes, obtained from patients with 
rheumatoid arthritis, in spite of proliferative responses 
comparable to that found in tuberculous pleural effusions. 
These observations are compatible with previous reports 
indicating that the requirements for proliferation, and 
generation of cytotoxicity, are different (144,145). 
The FPO-specific kill observed on day 6 in two patients with 
non-tuberculous effusions probably reflected previous 
infection or recent exposure without active infection. This 
contrasted strongly with our observations in active 
infection where in-vivo priming resulted in accelerated 
secondary responses observed in-vitro. 
It has previously been shown that FPO-stimulation of PBL 
( from normal donors as well as patients with leprosy or 
pulmonary tuberculosis) results 
antigen-specific cytotoxicity, 
independent killing (46-48). The 
to the effects of CD16+ NK and 
in the generation of both 
as well as antigen-
latter has been attributed 
LAK cells ( 46), and also 
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occurs in mixed lymphocyte cultures. Although strong NK-like 
activity was demonstrated against K562 target cells in 4-
hour chromium release assays, cytotoxicity which was 
observed in simultaneously performed 15-hour chromium 
release assays, was significantly antigen-specific. It was 
also major histocompatibility complex-restricted (Table 
4. 5), as has been reported in patients with leprosy ( 46). 
Furthermore, subset fractionation experiments showed that 
lysis of PPD-pulsed monocytes was mediated almost 
exclusively by CD4+ cells, in agreement with previous 
reports (46,47). Indeed, using the identical culture system 
as employed here, it has recently been shown that 
stimulation by PPD results in the generation of co4+15-
cytotoxic effector cells ( 48). We found that antigen non-
specific kill was also almost totally abrogated in the co4+ 
subset (Table 4.4), consistent with the finding that antigen 
non-specific killers are negative for both CD4 and CD8 
markers. It is therefore likely that antigen non-specific 
cytotoxicity was mediated by LAK cells. 
The data shown here may also have diagnostic and therapeutic 
implications. Firstly, the observation of accelerated 
proliferative and cytotoxic cellular immune responses only 
in patients with tuberculosis suggests a potential 
diagnostic role. The sensi ti vi ty and specificity of these 
observations are further evaluated in chapter 6. Secondly, 
conventional anti-tuberculous therapy is prolonged and 
compliance is frequently a major problem, and patients with 
multiple resistance to anti-tuberculous drugs frequently 
require prolonged hospitalization. Some patients also have 
persistent antigen secretion by circulating adherent cells 
long after full anti-tuberculous therapy (chapter 2). It may 
be possible to accelerate recovery in these patients if in-
vivo cytotoxicity can be boosted by the administration of 
subcutaneous lymphokines. This has already been achieved in 
patients with Leprosy (46). 
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CHAPTER 5 
FAILURE TO DEMONSTRATE PPD OR BCG-STIMULATED CD8 MEDIATED 
CYTOTOXICITY BY THE INTRODUCTION OF PPD OR BCG INTO THE 
CLASS I PATHWAY OF ANTIGEN PRESENTATION 
5.1. ABSTRACT 
Despite theoretical considerations, experimental 
confirmation of FPO-specific CDS mediated cytotoxicity has 
not been forthcoming in humans. One possible explanation for 
this difficulty is that in-vitro exogenously added antigen 
enters only the class II pathway of antigen processing. The 
activation of cos+ CTL requires antigen to be presented in 
the context of MHC class I. This has been experimentally 
realized by the introduction of soluble protein directly 
into the cytoplasm by using osmotic changes to lyse antigen 
containing pinosomes. This technique was employed to 
determine if PPD or ECG-specific cos+ CTL could be 
generated. A 4-hour chromium release 
adherent cells targets was used to measure 





lysis could be 
Having demonstrated CD4 mediated lysis (chapter 4), evidence 
for CD8 mediated lysis was sought since experimental 
evidence for CD8 mediated cytotoxicity is lacking in humans 
(12,53). 
cos+ CTL recognize antigen in association with MHC class I 
products. Thus the failure to demonstrate CD8 mediated 
cytotoxicity in-vitro may be due to the fact that 
exogenously added antigen enters the MHC class II pathway of 
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antigen processing. Recently it has been shown that 
exogenously added soluble protein can be made to enter the 
class I pathway of antigen presentation by the introduction 
of antigen directly into the cytoplasm of cells (55). This 
can be achieved by relatively brief (10 minutes) exposure of 
APC to antigen containing hypertonic medium (55). This 
results in the uptake of antigen in hypertonic medium into 
pinosomes (55). The pinosomes can then be lysed by returning 
the APC to isotonic medium (55). By this technique, class I 
restricted antigen presentation has been demonstrated after 
6 hours (55). Class I restricted antigen presentation can be 
observed even sooner if APC are exposed to hypotonic medium 
immediately after exposure to antigen containing hypertonic 
medium since this causes osmotic rupture of pinosomes and 
"cytoplasmic loading" ( 55) . Targets cytoplasmically loaded 
with antigen have been shown to express class I associated 
antigen for up to 2 days (55). 
In this section the attempted generation of cos+ CTL, by the 
introduction of PPD or BCG directly into the MHC class I 
pathway of antigen presentation, is discussed. 
5.3. MATERIALS AND METHODS 
5.3.1. Generation of PPD or ECG-primed CDB+ effectors 
PPD (5 mg/ml or 30mg/ml, Connaught laboratories) or BCG 
(30mg/ml, State Vaccine Institute, R.S.A., 20-40 
organisms/ml) was dissolved in hypertonic medium made up as 
follows: O.SM sucrose (BDH 10274, BDH LTD, Poole, England) 
10% w/v polyethylene glycol 1000 (BDH 29544) and lOmM Hepes 
buffer (lM; pH 7.2; Flow 16-884-49; Flow Laboratories LTD, 
Irvine, Ayrshire, Scotland) in RPM! 1640 medium. The 
relatively high concentrations of antigen were chosen 
because previous data indicated that cytotoxicity was 
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significantly lower when less than 3 mg/ml of antigen were 
used for cytoplasmic loading (55). PBMC obtained from known 
PPD responsive control subjects were plated in 12 well 
sterile tissue culture plates (Nunc, Kamstrup, Denmark) at a 
concentration of 1 x 106/well. After 1-2 hours the NAC were 
removed from each well individually and the adherent cells 
were washed gently 3 times with PBS. Prewarmed PPD or BCG 
containing hypertonic medium was added to each well of 
adherent cells and incubated for 10 minutes at 37°c. Some 
adherent cells were exposed to the same dose of PPD or BCG 
in isotonic complete medium. The adherent cells were then 
washed 4 times with PBS and the corresponding NAC were added 
back. The cultures were incubated for 6 days at 370c in a 
humidified atmosphere containing 5% CO2. 
5.3.2. Preparation of targets by osmotic lysis of pinosomes 
Target cells were day 6 autologous adherent cells of PBMC 
that had been plated in 96-well U-bottomed tissue culture 
plates (Nunc, Kamstrup, Denmark). Approximately 10% adhered. 
This number was used for calculating E/T ratios. 
Approximately 18 hours prior to the assay, 100µ1 of varying 
concentrations of prewarmed PPD containing hypertonic medium 
(as prepared above) was added to the target cells and 
incubated for 10 minutes. Some target cells were not exposed 
to hypertonic medium. These targets were labelled with the 
same dose of PPD or BCG in the conventional way (i.e. in 
isotonic complete medium). The targets were then washed 4 
times with prewarmed PBS and labelled with 6 uCi of Slsodium 
chromate (specific activity 3.7-13Gq/mg, Amersham 
International, Amersham, UK) in isotonic complete medium and 
incubated at 370c in a humidified atmosphere containing 5% 
CO2 until used in the assay approximately 18 hours later. 
5.3.3. Cytotoxic assay 
101 
The targets were washed 3 times with prewarmed complete 
medium and effectors were added in triplicate to the target 
cells at varying E/T ratios (10:1, 3:1 and 1:1). Wells with 
medium only were used for the determination of spontaneous 
release. Some plates were spun at 150G for 5 minutes. The 
assays were then incubated at 370c in a humidified 
atmosphere containing 5% CO2, 4 hours later the total 
supernatant content of each well was transferred to a 
disposable counting tube (Greiner, Nurtingen, West Germany) 
and 100µ1 of triton-X was added to the remaining adherent 
cells for the determination of maximum release. After 3 
hours the total volume of triton-X was transferred to 
similar tubes and the samples were counted in a gamma 
counter (Packard, auto-gamma scintillation spectrometer). 
The percentage-specific killing for each individual well was 
calculated as follows: percent specific lysis = (test 
cpm/ (test cpm + cpm after triton-X treatment of the same 
well)] x 100% - percent spontaneous release. The percentage 
spontaneous release was calculated as follows: cpm in 
spontaneous release well/(cpm in spontaneous release well+ 
cpm after triton-X treatment of the same well) x 100%. 
5.4. RESULTS 
5.4.1. Activation of effector cells 
By using the technique described above, effector cells were 
successfully activated as determined by inverted phase 
microscopy. Numerous activated blasts were also observed 
under light microscopy. 
5.4.2. Failure to demonstrate significant cytotoxicity 
Only low levels of cytotoxicity were generated in this 
system (Table 5.1, 5.2, 5.3, 5.4). By contrast, the 
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Table 5.1. Cytotoxicity, against autologous adherent targets 




ALLY LOADED WITH PPD: 
EXP.l: PPD Smg/ml 




EXP.1: PPD Smg/ml 
EXP.2: PPD 30mg/ml 





















Results are expressed as the mean percentage specific lysis 
of triplicate cultures as described in materials and 
methods. SD were mostly less than 10%. 
All experiments were performed at an ef fee tor to target 
ratio of 10:1 
Table 5.2. Cytotoxicity, against autologous adherent targets 
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Results are expressed as the mean percentage specific lysis 
of triplicate cultures as described in materials and 
methods. SD were mostly less than 10%. 
All experiments were performed at an ef fee tor to target 
ratio of 10:1 
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Table 5.3. Cytotoxicity, against autologous adherent targets 

























Results are expressed as the mean percentage specific lysis 
of triplicate cultures as described in materials and 
methods. SD were mostly less than 10%. 
All experiments were performed at an effector to target 
ratio of 10:1 
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Table 5.4. Cytotoxicity, against autologous adherent targets 








PERCENT SPECIFIC LYSIS 
OF TARGETS PULSED WITH: 
BCG No antigen 
15 0 
18 7 
Results are expressed as the mean percentage specific lysis 
of triplicate cultures as described in materials and 
methods. SD were mostly less than 10%. 
All experiments were performed at an effector to target 
ratio of 10:1 
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percentage specific lysis at the same E/T ratio ( 10: 1), 
using conventionally stimulated effectors and targets 
conventionally pulsed with 10 ug/ml PPD, increased to 35% in 
a parallel 15-hour chromium release assay (exp. 2 in Table 
3. 4). 
No significant differences in percentage lysis was observed 
when conventionally primed effectors, or effectors primed 
with APC cytoplasmically loaded with PPD, were directed 
against targets cytoplasmically loaded with PPD (Table 5.1). 
Similarly, no significant differences were observed when 
either effector was directed against conventionally pulsed 
targets (Table 5.2). 
5.5. DISCUSSION AND CONCLUSIONS 
The data indicates that only low levels of PPD-specif ic 
cytotoxicity were observed in 4-hour chromium release 
assays. This was the case even when APC, both used as 
targets and for the priming of effectors, were subjected to 
osmotic lysis of pinosomes. This procedure, theoretically at 
any rate, ought to have resulted in the introduction of 
antigen directly into the cytoplasm, and therefore into the 
class I pathway of antigen presentation. These observations, 
therefore, suggest that cos+ CTL were not significantly 
generated in this system. 
This conclusion is based on the assumption that cos+ cells 
would be responsible for any significant cytotoxicity over 
and above that observed by conventionally primed effectors 
and targets in 4-hour chromium release assays. The rationale 
for this assumption was a series of prior experiments 
demonstrating that CD4+ CTL only showed low levels of lysis 
at 4 or 7 hours (Table 3.4). Peak cytotoxicity was, in fact, 
only observed at 15 hours (Table 3. 4). On the other hand, 
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cos+cells were shown to be responsible for the cytotoxicity 
measured in a 4-hour chromium release assay, when targets 
were pulsed by using the technique of cytoplasmic loading by 
osmotic rupture of pinocytic vesicles (55). 
The failure to demonstrate FPO-specific cos+ CTL may 
indicate that they are not important in the immune response 
to mycobacterial infection. No firm conclusions can be 
drawn, however, since no positive control which 
unequivocally demonstrated class I association of antigen 
was available in these experiments. The successful 
activation of effector T lymphocytes by exposure to APC 
cytoplasmically loaded with PPO or BCG ( 5. 4 .1) does not 
unequivocally demonstrate that antigen entered into the 
class I pathway of antigen presentation. It is likely that 
antigen also entered the class II pathway in spite of 
osmotic lysis of pinocytic vesicles since peripheral blood 
monocytes are rich in class II expression (52). The 
inability to demonstrate cos+ CTL may still, therefore, be 
due to the failure to introduce sufficient antigen into the 
class I pathway of antigen presentation. 
Other potential explanations 
cos+ CTL exist. In view of 
for the failure to generate 
the fact that ovalbumin had 
already been successfully introduced into the class I 
pathway in previous animal studies (55), an attempt was made 
to use ovalbumin primed CTL directed against autologous 
ovalbumin labelled targets as a positive control. 
Unfortunately, this was not successful because control 
subjects showed very poor responses to ovalbumin. 
In previous studies, tryptic digests of native ovalbumin 
were unable to sensitize cos+ CTL for lysis while Cnbr 
digests of the same antigen were successfully used to 
sensitize cos+ CTL ( 55). The nature of PPO and BCG may 
preclude entry into the class I pathway of antigen 
presentation and may, therefore, be responsible for the 
failure to generate ens+ eTL. 
In tuberculosis, ens+ eTL have been generated only in animal 
studies using bone marrow macrophages as targets and it is 
thought that this may be due to the unique target cells 
employed ( 54) . The studies describing the introduction of 
antigen into the class I pathway of antigen presentation by 
osmotic lysis, used the class II negative target EL4 (55). 
It is therefore, also possible that ens mediated 




THE KINETICS OF PPD STIMULATED LYMPHOCYTE PROLIFERATION: A 
COMPARISON OF PLEURAL EFFUSION LYMPHOCYTES AND AUTOLOGOUS 
PERIPHERAL BLOOD 
6.1. ABSTRACT 
The diagnosis of tuberculous pleuritis is based on pleural 
biopsy and culture. These techniques are invasive and not 
always successful. In this section, results of in-vitro 
proliferative responses of PEL and corresponding PBL to PPD 
and SK-SD were assessed on day 3 and day 6 of culture by 
[3H]thymidine incorporation. PEL from a large number (65%) 
of patients with tuberculous pleuritis had an accelerated 
proliferative response to PPD. The finding was also specific 
in that no patients with non-tuberculous effusions 
demonstrated the phenomenon. These findings may be of 
diagnostic significance in patients with tuberculous 
pleuritis. 
6.2. INTRODUCTION 
Pleural biopsy is an invasive procedure not without 
complications (146). Suitable material for histology is not 
always obtained and culture of mycobacteria for diagnosis 
takes six weeks. Furthermore, it has been demonstrated that 
in 20-40% of patients with tuberculosis, and 40-60% with 
neoplasia, a definitive diagnosis cannot be made after 
closed pleural biopsy (146-149). Thus cellular immune 
studies which yield diagnostic information would almost 
certainly be useful in the clinical setting. 
Having noted accelerated kinetics of proliferation and 
cytotoxicity in a small group of patients with tuberculous 
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pleuritis (chapter 4), this study was undertaken to 
determine the extent of the phenomenon. Because the 
phenomenon was noted to be unique to tuberculous pleuritis, 
the specificity and sensitivity was evaluated with respect 
to its diagnostic significance. 
Several studies have examined cellular immune responses in 
pleural effusions (138-141,150,151). These studies have 
documented a significantly greater proliferative response in 
the pleural effusion than in the corresponding peripheral 
blood (138,139,150,151). None have, however, studied the 
kinetics of the proliferative response to PPD, Spontaneous 
lymphocyte proliferation has also not been systematically 
studied in pleural effusions. Following on our observations 
in the peripheral blood ( chapter 2), the phenomenon was 
studied in tuberculous pleuritis. 
6.3. MATERIALS AND METHODS 
6.3.1. Patient population 
Pleural fluid and peripheral blood samples were 
simultaneously obtained at the time of closed pleural biopsy 
in 31 patients with newly diagnosed tuberculous pleural 
effusions, seen at Groote Schuur Hospital between May and 
December 1989. Only cases with proven diagnosis (culture 
positive or positive pleural biopsy) were included in this 
group. Pleural fluid was also obtained from 13 patients with 
non-tuberculous aetiologies (malignancy, 10 cases; non-
specific inflammation, 1 case; parapneumonic effusion, 1 
case; pulmonary infiltrate and eosinophilia, 1 case). 
6.3.2. Proliferation assay 
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PBL or PEL were separated on a Ficoll-Hypaque gradient and 
washed three times in PBS. PBL or PEL (1 x 105) were added 





in O. 2 ml of complete medium. 
with 3µg/ml PPD (Connaught 
Laboratories, Willowdale, Ontario, Canada) or SK-SD (1:200 
dilution, Lederle Lab., Wayne, N.J., U.S.A.). Some wells 
were left unstimulated for the determination of background 
proliferation. Cultures were incubated at 37 oc in a 
humidified atmosphere containing 5% CO2 and pulsed with 
Tritiated thymidine (2 µCi/well, Amersham, U.K.) either on 
day 3 or day 6 for the final 16-18 hours of incubation. The 
cells were harvested using an automated harvester (Titertek 
630), and radioactivity was measured using a liquid 
scintillation counter (Packard, Tricarb 4640). All assays 
were performed in triplicate. Results were expressed as 
difference in counts per minute (cpm) between antigen 
stimulated and unstimulated cells. A count of greater than 
3000 cpm was considered a significant response 
(approximately the sum of the mean and 3 standard deviations 
of 22 unstimulated normal controls). 
6.3.3. Statistical analysis 
Analysis of variance by comparison of means was used to 
calculate P values. 
6.4. RESULTS 
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6. 4. 1. Spontaneous lymphocyte proliferation in tuberculous 
effusions 
Twelve of 31 patients had significant (P < 0.01) spontaneous 
lymphocyte proliferation in the PEL (Table 6 .1). Five of 
these patients had significant (P < 0.01) spontaneous 
Table 6.1. Spontaneous lymphocyte proliferation in patients 




































































Results are expressed as mean cpm of [3H]thymidine 
incorporation by triplicate cultures of unstimulated 
lymphocytes in complete medium only. SD were mostly less 
than 10%. Results are shown for 12 out of 31 patients who 
were considered to have significant (greater than 3000 cpm) 
spontaneous lymphocyte proliferation in the pleural 
effusion. 
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lymphocyte proliferation both in the PEL and PBL ( Table 
6 .1). Two of these patients had higher spontaneous 
lymphocyte proliferation on day 3, in the PEL, than on day 6 
(patients A.S. and N.M. in Table 6.1). Of the remaining 19 
patients 4 had significant (P < 0.01) spontaneous lymphocyte 
proliferation in the peripheral blood only (Table 6.2). 
6. 4. 2. Spontaneous lymphocyte proliferation in non-
tuberculous effusions 
Spontaneous lymphocyte proliferation was not unique to 
tuberculous effusions. The phenomenon was seen in 8 of 13 
non-tuberculous effusions ( Table 6. 3) . The level of the 
proliferation was, however, much lower than that observed in 
tuberculous effusions (Table 6.1). Three patients had 
significant (P < 0.01) spontaneous proliferation both in the 
PBL and PEL (patients E.P., G.F. and R.M. in Table 6.3). 
Three patients had significant (P < 0.01) spontaneous 
proliferation in the PBL only (S.S., A.A. and C.A. in Table 
6. 3) . 
6. 4. 3. Response to PPD by PEL and PBL in patients with 
tuberculous pleuritis 
Ten percent (3 of 29 patients) did not respond significantly 
in the PBL (patient A.W. in Table 6.4 and patients R.D. and 
s. M. in Table 6.5). These patients were all significantly 
positive in the PEL (Tables 6.4 and 6.5). Thirteen percent 
of patients (4 of 31) had negative responses on day 6 but 
were clearly positive on day 3 (Table 6.5). 
6.4.4. Accelerated proliferative responses to PPD in 
tuberculous effusions 
Twenty of 31 patients demonstrated accelerated proliferative 
responses to PPD in PEL with higher responses on day 3 as 
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Table 6. 2. Patients with tuberculous pleuritis not showing 
significant spontaneous proliferation in the PEL. 
PBL PEL 
PATIENT DAY 3 DAY 6 DAY 3 DAY 6 
---------------------------------------------------------
B.L. 2040 1005 1285 444 
T.M. 984 1209 2145 758 
M.D. 1464 3607 1168 1066 
A.F. 602 710 899 875 
B. I. 1143 795 718 600 
M.M. 800 1030 2006 878 
A.G. 745 3962 1423 686 
T.B. 994 7504 1037 1078 
S.F. 684 3016 945 944 
A.W 1800 1702 725 847 
F.S. 599 2635 1048 982 
S.N. 712 2340 1415 2070 
D.K. 686 846 715 884 
o.x. 713 1384 905 1754 
J.D. ND* ND 1891 601 
N.M. 675 1048 626 627 
R.D. 982 550 1285 1114 
F.F ND ND 940 870 
J.M. 1298 1472 893 751 
Results are expressed as mean cpm of [3H]thymidine 
incorporation by triplicate cultures of unstimulated 
lymphocytes in complete medium only. SD were mostly less 
than 10%. 
PBL data are presented for comparison. 
* ' ND, not done. 
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Table 6.3. Spontaneous lymphocyte proliferation in patients 









































































Results are expressed as mean cpm of [ 3H] thymidine 
incorporation by triplicate cultures of unstimulated 
lymphocytes in complete medium only. SD were mostly less 
than 10%. 
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Table 6.4. Patients with tuberculous pleuritis not showing 
accelerated proliferative responses to PPD. 
PBL PEL 
PATIENT DAY 3 DAY 6 DAY 3 DAY 6 
----------------------------------------------------------
B.K. 12486 34422 98418 101011 
B.L. 50082 107396 22532 24593 
T.M. 2508 14093 57454 79657 
M.D. 1644 28475 33438 68458 
A.F. 703 11012 4144 7193 
B. I. 1638 30901 44432 70819 
M.M. 33586 217783 55793 94578 
A.G 5675 57059 41576 44254 
T.B. 2542 7643 15724 23554 
F.S. 245 14656 49096 58757 
A.W. -372 1924 30012 43690 
Results are expressed as difference in mean cpm, of 
[3H]thymidine incorporation by triplicate cultures, between 
antigen stimulated and unstimulated wells. SD were mostly 
less than 10%. Results are shown for 11 out of 31 patients. 
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Table 6. 5. Accelerated proliferative responses to PPD by PEL 
obtained from patients with tuberculous pleuritis. 
PBL PEL 
PATIENT DAY 3 DAY 6 DAY 3 DAY 6 
----------------------------------------------------------
S.F 2252 25568 20449 14951 
S.N. 71724 61965 48464 25660 
D.K. 8560 55298 68649 63214 
o.x. 3363 28686 16258 521 
J.D. ND* ND 48520 15875 
N.M. 55917 33999 40964 21792 
R.D. 827 1165 111023 34525 
F.F. ND ND 58365 9778 
J.M. 5553 21419 73335 37507 
K.P. 5651 6660 14233 8696 
c.c 7939 30272 90259 -19127 
F.G. 7470 2174 69880 -23635 
A.S. 52904 70712 139803 21886 
K.D. 853 10674 39504 14067 
M.H. 6208 6620 73432 13052 
H.T. 5392 23219 49330 14629 
N.M. 19028 43595 20679 13275 
B.D. 27469 62013 88802 13664 
M.N. 18345 161107 101973 21882 
S.M. 1242 -1905 5419 -20351 
Results are expressed as difference in mean cpm, of 
[3H]thymidine incorporation by triplicate cultures, between 
PPD stimulated and unstimulated wells. SD were mostly less 
than 10%. Results are shown for 20 of 31 patients who 
demonstrated higher proliferative responses, in the PEL, on 
day 3 than on day 6. 
*ND, not done. 
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compared to day 6 ( Table 6. 5) . Two of these patients also 
had accelerated responses in the PBL (S.N. and F.G. in Table 
6.5), By contrast, none of the patients with non-tuberculous 
effusions had an accelerated response to PPD in the PEL 
(Table 6.6). Only one patient had an accelerated response in 
the PBL. The accelerated responses were antigen-specific 
since the response to SK-SD demonstrated conventional 
kinetics in all patients tested (Table 6.7). 
6.5. DISCUSSION AND CONCLUSIONS 
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Tuberculosis is a disease almost entirely regulated by the 
cell-mediated immune response of the host (18). It is, 
therefore, not unreasonable to expect understanding of the 
cellular immune response to provide information of 
diagnostic significance. 
Three unique observations about the cell-mediated immune 
response are evident from the results in this section. 
Firstly, a subset of patients demonstrate significant 
spontaneous lymphocyte proliferation in the pleural effusion 
(Table 6.1). Secondly, a large number (65%) of patients with 
tuberculous pleuritis demonstrate an accelerated 
proliferative response to PPD (Table 6.4). Thirdly, a 
negative or low proliferative response on day 6 may not 
indicate a negative result, but that the in-vitro response 
had already peaked. 
One effect of the spontaneous lymphocyte proliferation, was 
to reduce the sensitivity of lymphocyte transformation 
indeces. The indeces were falsely depressed by the high 
spontaneous proliferation. Difference in mean cpm between 
antigen stimulated and unstimulated wells was therefore 
utilized, with difference in cpm exceeding 3000 cpm being 
considered significant. 
Table 6.6. Proliferative responses to PPD in patients with 
non-tuberculous effusions. 
PBL PEL 
PATIENT DAY 3 DAY 6 DAY 3 DAY 6 
---------------------------------------------------------
T.M. 632 2482 -549 -764 
s.s 1228 8468 235 977 
H.P. 433 101816 61661 73202 
A.A 17320 10258 1903 2692 
C.A 1042 -2092 -800 869 
N.S. 15928 26599 9336 12548 
E.P. -2378 651 -392 31020 
D.L. 2412 44669 5602 10873 
S.A. 35022 46908 -10670 -6828 
G.P. -416 144 -1664 4978 
N.S. 749 2324 2591 -7947 
G.F. 11547 102901 19441 213301 
R.M. 441 2095 4087 5913 
Results are expressed as difference in mean cpm, of 
[3H]thymidine incorporation by triplicate cultures, between 
antigen stimulated and unstimulated wells. SD were mostly 
less than 10%. 
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Results are expressed as difference in mean cpm, of 
[3H]thyrnidine incorporation by triplicate cultures, between 
antigen stimulated and unstimulated wells. SD were mostly 
less than 10%. 
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The spontaneous lymphocyte proliferation may either reflect 
in-vivo activation at the site of the pathology or 
persistent mycobacterial antigen secretion by antigen 
presenting cells ( chapter 2). Because repeated samples of 
PEL cannot be obtained from patients with tuberculous 
pleuritis, further characterization of the phenomenon at 
this site was not possible. 
An interesting observation was that all the patients with 
spontaneous lymphocyte proliferation had accelerated 
kinetics of proliferation to PPD. This suggests that the 
spontaneous proliferation is a manifestation of in-vivo 
activation. It follows, therefore, that the accelerated 
kinetics of proliferation is a secondary immune response. 
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The observation that PPD responses were negative on day 6 in 
some cases in the pleural effusion, but strongly positive on 
day 3, indicates the need to do kinetic studies when 
assessing the immune response in patients with tuberculous 
pleuri tis. Furthermore, the observation that some patients 
had compartmentalized immune responses to PPD, (i.e. 
negative responses in the blood, but positive in the 
effusion) indicates the necessity of studying the immune 
response at the site of the pathology. Observations in the 
peripheral blood alone may be misleading. 
The restriction of the accelerated proliferative responses 
to patients with tuberculous pleuritis underlines the 
diagnostic value of this observation. On the basis of this 
observation, an early diagnosis could have been made in 65% 
of patients with tuberculous pleuritis, using a relatively 
non-invasive procedure. It may even be possible to make a 
diagnosis within 3 days and 24 and 48 hour responses to PPD 
will have to be examined in this regard. Furthermore, it is 
likely that accelerated proliferative responses will also be 
observed at other sites such as asci tes and pericardial 




COMPARTMENTALIZATION OF THE CELLULAR IMMUNE RESPONSE TO THE 
RECOMBINANT 65 kDa HEAT SHOCK PROTEIN OF MYCOBACTERIUM BOVIS 
BCG IN PATIENTS WITH TUBERCULOUS PLEURITIS 
7.1. ABSTRACT 
Proliferative and cytotoxic responses to the recombinant 65 
kDa antigen of M. bovis BCG was analyzed. PEL and autologous 
PBL obtained from patients with tuberculous and non-
tuberculous pleuritis were stimulated in-vitro with the 
recombinant 65 kDa antigen. Proliferation was assessed by 
3[H]thymidine incorporation. In addition, PEL were activated 
in-vitro with the 65 kDa antigen and tested for CTL activity 
in a 15-hour chromium release assay. A high percentage (56%) 
of PEL obtained from patients with tuberculous pleuri tis, 
but not non-tuberculous pleuri tis, showed significant 
proliferative responses to the 65 kDa antigen. The response 
in autologous PBL was also significantly lower both in terms 
of number of patients responding and also intensity of the 
response. PEL activated with the 65 kDa antigen showed 
antigen-specific lysis of autologous targets. These results 
indicate compartmentalization of the immune response to the 
65 kDa antigen of M. Bovis BCG, and in addition, provide 
evidence for in-vivo involvement of this antigen in the 
immune response to M. tuberculosis. 
7.2 INTRODUCTION 
The recombinant 65 kDa heat shock protein of M. bovis BCG 
has been shown to be immunodominant in mice immunized with 
M. tuberculosis (70). Antigen-specific and non-specific CTL 
have been generated against 65 kDa treated target cells 
(46). However little is known about reactivity, by patients 
with tuberculous pleuritis, to this antigen. 
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More recently, spontaneous proliferation by hybridomas 
obtained from neonatal thymocytes has been shown to be due 
to recognition of the 65 kDa HSP (90). Thus the spontaneous 
lymphocyte proliferation observed in peripheral blood and 
pleural effusions ( chapters 2 and 6) may also be due to 
recognition of either mycobacterial HSP or the human 
homologue. Thus, reactivity to the the recombinant 65 kDa 
antigen of M. bovis BCG was studied in patients with 
tuberculous pleuritis. 
7.3 MATERIALS AND METHODS 
7.3.1. Patient population 
Pleural fluid and peripheral blood samples were 
simultaneously obtained at the time of closed pleural biopsy 
in 18 patients with newly diagnosed tuberculous pleural 
effusions, 
December 
seen at Groote Schuur Hospital between July and 
1989. Pleural biopsy revealed granulomatous 
pleuritis with the presence of M. tuberculosis in all cases. 
Pleural fluid was also obtained from 7 patients with non-
tuberculous aetiologies (malignancy, 6 cases and non-
specific inflammation, 1 case). Peripheral blood samples 
were also obtained from control subjects for the analysis of 
cytotoxicity. These controls were the same as those employed 
in chapter 6. 
7.3.2. Proliferation assay 
PBL or PEL were separated on a Ficoll-Hypaque gradient and 
washed three times in PBS. Cells (1 x 105) were added to 
wells of 96 well round bottomed sterile tissue culture 
plates ( Flow Laboratories) in O. 2 ml of complete medium. 
Cells were stimulated with 5 µg/ml of the 65 kDa HSP of M. 
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Bovis BCG ( a kind gift from Dr J. D. A. Van Embden, WHO 
IMLEPP programme) or 3µg /ml PPD ( Connaught Laboratories, 
Willowdale, Ontario, Canada) except for some wells which 
contained responder cells alone for the determination of 
background proliferation. Cultures were incubated at 37 °c 
in a humidified atmosphere containing 5% CO2 and pulsed with 
Tritiated thymidine (2 µCi/well, Amersham, U.K.) on day 3 
and day 6 for the final 16-18 hours of incubation. The cells 
were harvested using an automated harvester (Titertek 630), 
and radioactivity was measured using a liquid scintillation 
counter (Packard, Tricarb 4640). All assays were performed 
in triplicate. Results were expressed as lymphocyte 
transformation indices (LTI). The LTI was calculated as 
follows: LTI = mean counts per minute in antigen stimulated 
wells/mean counts per minute in unstimulated wells. An LTI 
of greater than 3 was considered a significant response. 
7.3.3. Cytotoxicity assay 
The cytotoxic capacity of effector cells which had been 
stimulated for 6 days with the 65 kDa HSP of BCG in 24 well 
tissue culture plates (Nunc, Kamstrup, Denmark) was assayed 
as described in section 3. 3. 3. Target cells were labelled 
with 10 µg/ml 65 kDa antigen, lOµg/ml PPD or a 1:100 
dilution of SK-SD. Some target cells did not receive 
antigen. 
7.3.4. Statistical analysis 
Statistical analysis was performed using Kruskal-Wallis one-
way analysis of variance for continuous measurements. 




7.4.1. PPD and 65 kDa antigen reactivity in TB pleuritis. 
Fig. 7.1 compares the responsiveness of PEL and PBL obtained 
from 18 patients with proven Tuberculosis, to stimulation by 
the recombinant 65 kDa antigen or PPD. Results are expressed 
as the percentage of patients whose lymphocytes demonstrate 
a significant response to antigen, defined as an LTI > 3. 
Fifty six percent (10 of 18) of tuberculous effusions tested 
demonstrated significant responses to the 65 kDa antigen 
(Fig. 7.1). Only 11% (2 of 18) of autologous PBL responded. 
This difference was statistically highly significant ( p < 
0. 003). The response to PPD was much greater in both PEL 
(100%) and PBL (94%) (Fig. 7.1). 
7.4.2. The intensity of the response to 65 kDa is greater at 
the site of the pathology. 
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The magnitude of the proliferative response by PEL and PBL 
to the 65 kDa antigen and PPD were compared. Reactivity was 
significantly higher in pleural fluid than in peripheral 
blood, with mean LTI + standard error of 10. 16 + 3. 16 vs. 
1.6 + 0.2, respectively (n=18, p < 0.01). While reactivity 
to PPD tended to be higher in pleural f 1 uid than in the 
peripheral blood (mean LTI + standard error of 50. 3 + 8. 8 
vs. 38.4 + 12.8), this difference did not achieve 
statistical significance. 
7. 4. 3. The 65 kDa antigen shows greater specificity when 
compared to PPD. 
Lymphocytes from 3 of 7 non-tuberculous effusions showed 
reactivity to PPD (Table 7.1). By contrast none of the non-
tuberculous effusions demonstrated significant reactivity to 
the 65 kDa antigen (Table 7.2). Similar results were 
obtained for PBL obtained from these patients (Table 7.2). 
Fig. 7.1. Lymphocytes obtained from patients with 
Tuberculous pleuritis were stimulated with PPD or the 
recombinant 65 kDa mycobacterial antigen as shown on the x-
axis. The percentage of patients showing a significant 
response (LTI > 3) is shown on the y-axis. The response by 

















Table 7.1. Proliferative responses of PEL and PBL, obtained 
from patients with non-tuberculous effusions, to PPD. 
PBL PEL 
Patient DAY 3 DAY 6 DAY 3 DAY 6 
------------------------------------------------------------
1 10 27 11 39 
2 0.6 1 0.7 1. 5 
3 6 2 3 2 
4 19 42 72 77 
5 17 13 4 6 
6 1 1 1 3 
7 3 54 3 2.5 
The results are expressed as lymphocyte transformation 
indexes ( LTI) . The LTI was calculated as follows: mean 
counts per minute of [3H]thymidine incorporation in antigen 
stimulated wells/mean counts per minute of [3H]thymidine 
incorporation in unstimulated wells. An LTI of greater than 
3 was considered a significant response. 
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Table 7.2. Proliferative responses of PEL and PBL, obtained 
from patients with non-tuberculous effusions, to the 
recombinant 65 kDa heat shock protein of M. Bovis BCG. 
PBL PEL 
Patient DAY 3 DAY 6 DAY 3 DAY 6 
1 1 1 1 2 
2 2.5 19 0.6 0.6 
3 0.6 1 1,4 1 
4 2.6 1. 2 1. 2 0.5 
5 2.8 1. 8 3 0.6 
6 0.4 1 2 0.8 
7 2 2.7 0.8 2.6 
The results are expressed as lymphocyte transformation 
indexes (LTI). The LTI was calculated as follows: mean 
counts per minute of [3H]thymidine incorporation in antigen 
stimulated wells/mean counts per minute of [3H]thymidine 
incorporation in unstimulated wells. An LTI of greater than 
3 was considered a significant response. 
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7.4.4. Reactivity to 65 kDa demonstrates conventional 
kinetics. 
Because accelerated kinetics of proliferation were observed 
by PEL stimulated with PPD (chapter 6), the kinetics of the 
response to the 65 kDa antigen was determined. Reactivity to 
the 65 kDa antigen, however, demonstrated conventional 
kinetics (Table 7.3). 
7.4.5. 65 kDa primed effectors demonstrated antigen specific 
cytotoxicity at the site of the pathology. 
65 kDa labelled targets were significantly lysed by 
autologous 65 kDa primed effectors in all three patients 
tested ( Table 7. 4) . PPD labelled targets were also 
significantly, al though less efficiently, lysed (Fig. 7. 2). 
Some antigen non-specific kill was observed at high E/T 
ratios (Table 7.4, Fig.7.2 and Fig. 7.3). A similar pattern 
was seen in control PBL (Fig. 7.4). 
7.5 DISCUSSION AND CONCLUSIONS 
The 65 kDa HSP of BCG is a major immunogenic component of M. 
Bovis ECG, M. Tuberculosis, and M. Leprae and is frequently 
recognized by murine and human B cells and helper T cells 
(47,53,67-69). Studies in mice immunized with M, 
tuberculosis have demonstrated that 20% of mycobacteria-
reacti ve T lymphocytes recognize this molecule (70). Amino 
acid sequence determination has revealed that the 65 kDa 
antigen is identical in M. bovis and M tuberculosis, and 
highly homologous to the Eschericia coli HSP GroEL (70,71). 
The human homologue has also been found to be 50% identical 
with the mycobacterial protein (72). 
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Table 7.3. Proliferative responses of PEL and PBL, obtained 
from patients with tuberculous pleuritis, to the recombinant 


































































































The results are expressed as lymphocyte transformation 
indeces (LTI). The LTI was calculated as follows: mean 
counts per minute of [3H]thymidine incorporation in antigen 
stimulated wells/mean counts per minute of [3H]thymidine 
incorporation in unstimulated wells. An LTI of greater than 
3 was considered a significant response. 
ND, not done 
Table 7.4. Mean cytotoxicty by 65 kDa stimulated PEL 
obtained from patients with tuberculous pleuritis. 
% SPECIFIC LYSIS OF 
TARGETS PULSED WITH: 
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Fig. 7.2. Lysis of autologous adherent cell targets labelled 
with 65 kDa (+), PPD (e), SK-SD (6) or unlabelled (£) by 
65 kDa stimulated PEL effector cells obtained from a patient 
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Fig. 7.3. Lysis of autologous adherent cell targets labelled 
with 65 kDa (+), SK-SD (e) or unlabelled (6) by 65 kDa 
stimulated PEL effector cells obtained from a patient with 












0.3 1 3 10 
E/T Ratio 
135 
Fig. 7.4. Lysis of autologous adherent cell targets labelled 
with 65 kDa {O), SK-SD {e) or unlabelled {L) by 65 kDa 
stimulated PBL effector cells obtained from a normal 
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It has, therefore, been considered a potential candidate for 
a subunit vaccine. Doubt about its widespread application as 
a vaccine arose when a study showed that the antigen was 
immunodominant in only 20% of 47 individuals tested (47). 
However, the above mentioned study was performed on cells 
obtained from peripheral blood (47). The findings contained 
herein demonstrate that, at the site of the pathology, a 
much higher percentage of patients (56%) are responsive to 
the 65 kDa antigen. In addition, it is shown that only 11% 
respond in the peripheral blood. The high response rate was 
specific to tuberculous pleural effusions since no 
reactivity was observed in seven non-tuberculous effusions, 
despite the fact that three of these patients responded to 
PPD (Table 7.2). 
The much lower response to the 65 kDa antigen observed in 
the peripheral blood of patients with tuberculous pleuritis 
may reflect suppression since it is known that both 
monocytes and T cells may function as suppressor cells in 
tuberculous peripheral blood (41,42,151). The low response 
rate in the blood may, in fact, be beneficial to the host 
since the 65 kDa antigen has been implicated in autoimmune 
disease (72,75,76). Suppression in the PBL, therefore, may 
function to reduce the potential for widespread autoimmune 
reactions to occur. 
Although limited to three patients, the finding that the 65 
kDa antigen serves as a target for 65 kDa primed effector 
CTL (Table 7.4, Fig.7.2 and Fig. 7.3) is in agreement with a 
previous study (47). However, the 65 kDa primed PEL obtained 
from these patients did not demonstrate the high levels of 
antigen non-specific kill observed in other studies (47-48). 
Similarly, only low levels of antigen non-specific kill was 
observed in control peripheral blood (Fig. 7.3). One reason 
for this difference may be that the targets in the previous 
study were "stressed" in some way, since it has been 
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demonstrated that monocytes "stressed" by exposure to IFN-6 
express cross-reactive epitopes to the recombinant 65 kDa 
antigen ( 74). It has been shown that these cross-reactive 
epi tapes can be presented to CTL with reactivity to the 
recombinant 65 kDa antigen (74). 
In conclusion, these results demonstrate that PEL in a high 
percentage (56%) of patients with tuberculous pleuritis, 
respond to the 65 kDa antigen. In addition, PEL primed with 
the 65 kDa antigen demonstrated antigen-specific cytolysis. 
These findings confirm that 65 kDa antigen responsiveness is 
more widespread than has been previously thought, and 
suggests that it is a candidate for a subunit vaccine. 
Furthermore, the marked compartmentalization of the immune 
response seen here emphasizes the importance of evaluating 




FINAL DISCUSSION AND CONCLUSIONS 
Several new findings are described in this thesis. These 
include: ( 1) persistent in-vitro spontaneous proliferation 
by peripheral blood and pleural effusion lymphocytes, ( 2) 
accelerated and augmented proliferative and cytotoxic 
cellular immune responses in tuberculous pleural effusions, 
and (3) enhanced reactivity to the recombinant 65 kDa 
antigen of M. Bovis BCG by pleural effusion lymphocytes. 
These observations substantiate the pivotal role played by 
cellular immune mechanisms in immunity following 
mycobacterial infection. 
Several characteristics of the spontaneous proliferation 
implicated a role for APCs and antigen in its initiation. 
The exact nature of this antigen was not established but 
since the phenomenon was observed in patients with active 
tuberculosis, it is probable that the antigen was derived 
from mycobacteria. However, self-antigen cross-reactive with 
mycobacterial antigen could also account for the spontaneous 
proliferation. A known example of such an antigen is the 65 
kDa HSP (74). Thus the finding that reactivity to the 65 kDa 
antigen correlated with active disease ( chapter 7) could 
suggest that the antigen responsible for initiation of the 
spontaneous lymphocyte proliferation may indeed have been 
mycobacterial 65 kDa HSP or the human homologue. 
Consequently, future research will be aimed at isolating the 
spontaneously proliferating cells, and determining the 
nature of the T cell receptors employed and their antigen 
reactivity. It has been shown that the gamma-delta T cell 
receptor was exclusively used by spontaneously proliferating 
hybridomas obtained from neonatal thymocytes ( 90). These 
hybridomas were shown to respond to the 65 kDa HSP, but not 
other bacterial antigens, thus indicating that the 
spontaneous proliferation was a response to the 65 kDa HSP 
( 9 0) • 
Spontaneous lymphocyte proliferation would be significant 
irrespective whether due to endogenous human HSP or 
persisting mycobacterial antigen. The significance of the 
former is that it could account for destruction of self 
tissue even in the absence of ongoing infection, since it is 
evident that the 65 kDa antigen can prime CTL and also serve 
as a target for such CTL (Chapter 7). The significance of 
the latter is that persisting antigen (whether 65kDa or 
other mycobacterial antigen) would represent a failure by 
cell mediated immunity to clear infected macrophages. This 
would therefore imply a failure of the candidate mechanisms 
employed in the clearance of parasi ti zed macrophages i.e. 
IFN-6 mediated macrophage activation, cytokine mediated 
macrophage destruction and/or cell mediated macrophage 
lysis. For reasons discussed earlier in this work, cell 
mediated cytolysis was considered the most important 
mechanism. Thus it was postulated that defective cell 
mediated cytolysis could have accounted for the failure to 
clear infected macrophages in the patients with spontaneous 
lymphocyte proliferation. As a result of technical 
difficulties (including particularly ill patients who could 
not be repeatedly venesected for the provision of target 
cells and patients being lost to follow up) this hypothesis 
could not be pursued further in the patients with 
spontaneous proliferation. Nevertheless, the general 
hypothesis that cell mediated cytotoxicity was important for 
protection against mycobacteria was explored. 
Clear evidence was provided of augmented and accelerated 
PPD-specif ic cytotoxici ty in pleural effusion lymphocytes 
(Chapter 4). Since this resembled a secondary immune 
response, the implication was that cytotoxic T cells were 
being primed in-vivo. This is the first evidence implicating 
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an in-vivo role for cytotoxic T cells in human tuberculosis. 
Thus caseation within tuberculous granulomata may indeed 
result from the effects of CTL activity. Furthermore, 
antigen non-specific kill was also demonstrated and found to 
be likely to be due to NK activity (Chapter 4). The 
significance of this finding is that it may represent 
another mechanism responsible for tissue damage in pulmonary 
tuberculosis. 
The FPO-specific cytotoxic cells were found to be co4+ and 
MHC class II restricted ( Chapter 4). Attempts to generate 
cos+ CTL were not successful but no firm conclusions could 
be drawn since a positive control was lacking (chapter 5). 
However, the failure to unequivocally demonstrate FPO-
specific CDS mediated cytotoxicity was not unique as can be 
seen from the literature. It is possible that these 
observations reflect the actual in-vivo requirements for 
protection since M. Tuberculosis is not usually seen in 
cells other than professional phagocytes (13). Thus it may 
be that M. Tuberculosis exhibits a tropism for these cells 
and does not infect host parenchymal cells. Professional 
phagocytes carry the class II antigen and can therefore be 
recognized by CD4+ CTL (52). An alternative explanation is 
that host parenchymal cells die soon after becoming 
parasitized with M. Tuberculosis, due to enhanced TNF 
sensitivity, and thus there may be no need for CDS mediated 
cytotoxicity (13). The requirements in Leprosy on the other 
hand may be quite different since the bacterium is often 
seen in parenchymal cells ( 13). These cells usually only 
express the class I antigens and therefore are recognized by 
cos+ CTL. 
Reactivity to the 65 kOa protein was found to be 
compartmentalized and to correlate with active disease 
( Chapter 7). Antigen-specific cytotoxici ty by CTL primed 
with the recombinant 65 kDa protein of M. Bovis BCG was also 
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found to be directed against target cells treated with both 
the 65 kDa protein and PPD (Chapter 7). These findings serve 
to further 









may form a 
The accelerated proliferative response by PPD-stimulated 
lymphocytes was further analyzed for diagnostic value 
( Chapter 6). Sixty five percent of unselected tuberculous 
effusions were shown to have accelerated kinetics of 
proliferation. All of these were subsequently confirmed to 
have tuberculosis. The phenomenon was not seen in non-
tuberculous effusions and therefore has diagnostic value. 
These observations have already been extended to pericardial 
effusions and future efforts will be directed at a sci tes. 
The small yield of lymphocytes obtained from cerebrospinal 
fluid is likely to prove a major limitation in the setting 
of tuberculous meningitis. It would be important to 
determine if the assay could be microtized since the 
diagnosis of tuberculous meningitis remains a difficult 
clinical problem. Cellular assays are unfortunately 
expensive, labour intensive and require highly trained 
personnel. The clinical application for this test may 
therefore be limited to selected cases where a diagnosis 
cannot be made with more conventional tests. 
The observation that PPD-specific cytotoxicity is augmented 
and accelerated in tuberculous pleural effusions raises 
questions about cell mediated cytotoxicity in other clinical 
forms of tuberculosis. Thus it would be interesting to 
document this in future studies. For example, preliminary 
observations suggest that cytotoxicity is reduced in 
disseminated tuberculosis. It would be important to 







as has been 
( 4 6) • Studies 
would also have to be conducted to determine if such 
manipulation of the cytotoxic 
clinically beneficial responses. 
response resulted in 
Numerous complications exist with current chemotherapeutic 
regimes. Treatment lasts for 6-9 months and compliance is 
consequently a major problem. Drug related toxicity is a 
major limitation and multi-drug resistant strains of M. 
tuberculosis are also increasingly being encountered. Thus 
there is little doubt that additional modalities of therapy 
such as immunomodulation will be required to combat 
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